.png)
COVID-19 Evidence Reviews
as of 10/4/22
= living review
= draft/preprint | A review with this mark was peer-reviewed, described systematic search and study selection, and included critical appraisal of primary studies.
 latest update date
 |
select |
|
|---|---|---|
|
9/28/22
|
Zong X, Wang X, Liu Y, et al. | Front Med
Aim: To provide an overview of existing evidence on antiplatelet therapy in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/28/22
|
Zhu H, Li M, Tian C, et al. | Front Pharmacol
Aim: To summarize the effectiveness and safety of CHM in the treatment of mild/moderate COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/26/22
|
Kovacs EH, Tanczos K, Szabo L, et al. | Biomedicines
Aim: To assess whether higher dose (HD) compared with standard dose (SD) versions of thromboprophylaxis have different effects on clinical outcomes without jeopardizing the safety of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/26/22
|
Kiaei A, Salari N, Boush M, et al. | Life
Aim: To assess the impact and application of artificial intelligence on the identification of suitable drug combinations for treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/22/22
|
Reis S, Metzendorf M, Kuehn R, et al. | Cochrane Database Syst Rev
Aim: To assess the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid®) plus standard of care compared to standard of care with or without placebo, or any other intervention for treating COVID?19 and for preventing SARS?CoV?2 infection.
CANDIDATE THERAPEUTICS
|
|
|
9/20/22
|
Chien TJ, Liu CY, Chang YI, et al. | Front Pharmacol
Aim: To evaluate the efficacy of HM in the treatment of COVID-19 objectively. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/19/22
|
Casman C, Fitriani N, Gunawan D, et al. | Florence Nightingale J Nurs
Aim: To analyze the effectiveness of convalescent plasma therapy in children who are confirmed positive for coronavirus disease-2019.
CANDIDATE THERAPEUTICS
|
|
|
9/19/22
|
Reis S, Popp M, Schieber S, et al. | Thromb Res
Aim: To determine the safety and efficacy of anticoagulation at any dosage with standard low-dose prophylactic anticoagulation or no prophylaxis in COVID-19 patients regardless of disease severity and treatment setting.
CANDIDATE THERAPEUTICS
|
|
|
9/19/22
|
Almeida PRL, Person OC, Puga MEDS, et al. | Sao Paulo Med J
Aim: To evaluate the effectiveness and safety of tocilizumab for treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/19/22
|
Yulistiani, Neldi V, Suprapti B, et al. | J Pharm Pharm Sci
Aim: To analyze the efficacy and safety of anticoagulants for COVID-19 patients in the intensive care unit.
CANDIDATE THERAPEUTICS
|
|
|
9/19/22
|
Abolmaali M, Rezania F, Behnagh AK, et al. | Immunol Res
Aim: To assess different demographic, clinical, and neurophysiological aspects of patients with GBS following immunization with COVID-19 vaccines.
CANDIDATE THERAPEUTICS
|
|
|
9/12/22
|
Lee HJ, Lee JH, Cho Y, et al. | Int J Environ Res Public Health
Aim: To investigate the efficacy and safety of convalescent plasma (CP) transfusion against the coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
9/7/22
|
Taha AM, Shaarawy AS, Omar MM, et al. | J Transl Med
Aim: To evaluate the effect of Omega-3 on CRP change and CRP level in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/7/22
|
Martins-Filho PR, do Nascimento-Júnior EM, Barreto-Alves JA, et al. | Eur J Clin Pharmacol
Aim: To review the best evidence on the efficacy and safety of nitazoxanide in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/6/22
|
Webster KE, O'Byrne L, MacKeith S, et al. | Cochrane Database Syst Rev
Aim: To evaluate the benefits and harms of any intervention versus no treatment for people with acute olfactory dysfunction due to COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
9/6/22
|
O'Byrne L, Webster KE, MacKeith S, et al. | Cochrane Database Syst Rev
Aim: To assess the effects (benefits and harms) of interventions that have been used, or proposed, to treat persisting olfactory dysfunction due to COVID-19 infection. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/6/22
|
Choudhuri AH, Duggal S, Singh J, et al. | J Anaesthesiol Clin Pharmacol
Aim: To review the evidence on the safety and efficacy of convalescent plasma use in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/31/22
|
Sayfollahi S, Momeni Z, Bagherzadeh S, et al. | Research Square
Aim: To determine whether LDRT effectively treats COVID-19-associated pneumonia.
CANDIDATE THERAPEUTICS
|
|
|
8/30/22
|
Tang HJ, Weng TS, Chen YH, et al. | J Microbiol Immunol Infect
Aim: To investigate the clinical efficacy and safety of oral Janus kinase inhibitors (JAKis) in the treatment of hospitalized patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/29/22
|
Rezaei Tolzali MM, Noori M, Shokri P, et al. | Rev Med Virol
Aim: To determine the efficacy of tocilizumab in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/29/22
|
Tsermpini EE, Glamoclija U, Ulucan-Karnak F, et al. | Antioxidants
Aim: To extract the relevant genetic variants within the oxidative stress pathway associated with COVID-19 and the anti-oxidative therapies currently evaluated in the clinical trials for COVID-19 treatment, in particular clinical trials on glutathione and N-acetylcysteine.
CANDIDATE THERAPEUTICS
|
|
|
8/29/22
|
Huilei Zhao MD, Shanshan Huang MD, Shan Huang MD, et al. | Br J Clin Pharmacol
Aim: To assess the prevalence use of NSAIDs in the general COVID-19 population.
CANDIDATE THERAPEUTICS
|
|
|
8/29/22
|
Lai CC, Wang YH, Chen KH, et al. | Viruses
Aim: To compare the clinical efficacy and safety of anti-viral agents for the prevention of disease progression among non-hospitalized patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/25/22
|
Duo H, Li Y, Sun Y, et al. | Thromb J
Aim: To review the evidence on the efficacy and safety of therapeutic anticoagulation (T-AC) versus a lower dose, prophylaxis anticoagulation (P-AC) in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/22/22
|
Davoudi-Monfared E, Ahmadi A, Karimpour-Razkenari E, et al. | Am J Ther
Aim: To collect data about the necessity and safety administration of RDV in the setting of renal impairment.
CANDIDATE THERAPEUTICS
|
|
|
8/22/22
|
Nie Z, Sun T, Zhao F | Infect Drug Resist
Aim: To investigate the efficacy and safety of antiviral drugs in the treatment of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
8/22/22
|
Tahsini Tekantapeh S, Ghojazadeh M, Ghamari AA, et al. | Expert Rev Respir Med
Aim: To review the evidence on therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/18/22
|
Patel C, Parmar K, Patel D, et al. | Rev Med Virol
Aim: To investigate the effect of corticosteroids on mortality in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/16/22
|
Qian Z, Zhang Z, Ma H, et al. | Front Immunol
Aim: To assess whether convalescent plasma therapy could offer survival advantages for patients with novel coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/15/22
|
Montrucchio G, Balzani E, Lombardo D, et al. | J Clin Med
Aim: To clarify the use of MR-proADM in severe COVID-19 disease.
CANDIDATE THERAPEUTICS
|
|
|
8/10/22
|
Lim YJ, Khan U, Karpha I, et al. | EJHaem
Aim: To quantify the clinical outcomes of HCT recipients with COVID?19, as well as a comprehensive subgroup analysis to determine clinical factors associated with adverse outcomes.
CANDIDATE THERAPEUTICS
|
|
|
8/10/22
|
Brooks D, Schulman-Rosenbaum R, Griff M, et al. | Endocr Pract
Aim: To describe the management of glucocorticoid-induced hyperglycemia and to summarize available management strategies for dexamethasone-associated hyperglycemia in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/10/22
|
Sharifi A, Akbari Z, Shafie'ei M, et al. | Ophthalmic Plast Reconstr Surg
Aim: To review the evidence on retrobulbar injection of amphotericin B in patients with COVID-19 associated rhino-orbito-cerebral mucormycosis (CAM).
CANDIDATE THERAPEUTICS
|
|
|
8/9/22
|
Manoharan S, Ying LY | Can J Infect Dis Med Microbiol
Aim: To further understand the clinical benefits of baricitinib in the management of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/9/22
|
Liu J, Dong J, Yu Y, et al. | Front Public Health
Aim: To assess the effectiveness and safety of corticosteroids in hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/3/22
|
Aryana IGPS, Daniella D, Paulus IB, et al. | Ann Geriatr Med Res
Aim: To examine the effect of CP in older adults with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/2/22
|
Li M, Zhu H, Liu Y, et al. | Front Pharmacol
Aim: To comprehensively summarize the efficacy and safety of TCM in the treatment of severe/critical COVID-19 patients by systematically collecting available evidence from RCTs and observational studies.
CANDIDATE THERAPEUTICS
|
|
|
7/28/22
|
Arias M, Oliveros H, Lechtig S, et al. | Pharmaceuticals
Aim: To reevaluate the available evidence of the use of biologics as treatment candidates for the treatment of severe and advanced COVID-19 disease UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/28/22
|
Bücke P, Hellstern V, Cimpoca A, et al. | J Clin Med
Aim: To review the current evidence supporting the use of EVT for SVT on the basis of case presentations, with a focus on patient selection, treatment strategies and the effects of the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
7/27/22
|
Pitre T, Van Alstine R, Chick G, et al. | CMAJ
Aim: To compare the effectiveness of antiviral drugs for patients with nonsevere COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/27/22
|
Hernandez AV, Piscoya A, Pasupuleti V, et al. | Am J Med
Aim: To assess beneficial and harmful effects of monoclonal antibodies for COVID-19 treatment, and prophylaxis in exposed to SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
7/19/22
|
Yao W, Dong H, Qi J, et al. | EClinicalMedicine
Aim: To better understand the efficacy and safety of mesenchymal stromal cells (MSCs) in treating severe/critical patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/18/22
|
Lan SH, Hsu CK, Lai CC, et al. | Ann Med
Aim: To assess the usefulness of colchicine in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/18/22
|
Hernandez AV, Ingemi J 3rd, Sherman M, et al. | Arch Med Sci
Aim: To review the efficacy of hydroxychloroquine as early treatment for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/18/22
|
Xue C, Liu Z, Xiang H, et al. | Altern Health Ther Med
Aim: To determine the efficacy of interferon (IFN)-based therapy for coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/14/22
|
Siemieniuk RAC, Bartoszko JJ, Ge L, et al. | BMJ
Aim: To compare the effects of treatments for coronavirus disease 2019 (covid-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/12/22
|
Raviraj KG, Shobhana SS | Forensic Sci Med
Aim: To determine the findings obtained and inferences drawn from various studies published globally among patients who died due to COVID19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/22
|
Javed A, Karki S, Sami Z, et al. | Biomed Res Int
Aim: To explore the therapeutic potential and safety of using MSC obtained by isolation from health cord tissues in the treatment of patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/22
|
Chen CH, Wang CY, Wang YH, et al. | Expert Rev Clin Pharmacol
Aim: To review the evidence on the effect of inhaled corticosteroids (ICS) on the clinical outcomes of patients with coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
7/6/22
|
Lai CC, Chen WC, Chen CY, et al. | Expert Rev Anti Infect Ther
Aim: To investigate the effectiveness of IVIG in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/5/22
|
Sun XH, Zhang S, Yang Z, et al. | Chin J Integr Med
Aim: To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/23/22
|
Li L, Xie H, Wang L, et al. | Chin Med
Aim: To systematically review the clinical efficacy and safety of Chinese herbal medicine (CHM) with and without Western medicine (WM) for different severity of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/23/22
|
Ji Z, Hu H, Qiang X, et al. | Am J Chin Med
Aim: To compare the efficacy of different traditional Chinese medicine (TCM) therapies for the treatment of coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/21/22
|
Qin J, Wang G, Han D | Int J Infect Dis
Aim: To determine the efficacy of therapeutic plasma exchange (TPE) on mortality in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/21/22
|
Li Y, Xiao P, Liu N, et al. | Front Pharmacol
Aim: To integrate the existing evidence to evaluate the efficacy and safety of LQ paired with western medicine in the treatment of patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/21/22
|
Tan RSJ, Ng KT, Xin CE, et al. | J Cardiothorac Vasc Anesth
Aim: To evaluate the use of high-dose versus low- dose corticosteroids on the mortality rate of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/21/22
|
Molina-Carballo A, Palacios-López R, Jerez-Calero A, et al. | Curr Issues Mol Biol
Aim: To analyze the knowledge and evidence that exists after the use of melatonin in the treatment of SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
6/15/22
|
Cao B, Jing X, Liu Y, et al. | J Thorac Dis
Aim: To summarize the available data on the association between the severity of (COVID-19) and routine blood indicators, inflammatory, biochemical parameters and coagulation parameter.
CANDIDATE THERAPEUTICS
|
|
|
6/14/22
|
Kramer A, Prinz C, Fichtner F, et al. | Cochrane Database Syst Rev
Aim: To assess the effects of systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo) on clinical outcomes in individuals (outpatient or in-hospital) with any severity of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/9/22
|
Batista DR, Floriano I, Silvinato A, et al. | J Bras Pneumol
Aim: To answer questions related to the use of anticoagulants in the treatment of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
6/8/22
|
Fei Z, Chen Z, Du X, et al. | Transfus Med Hemother
Aim: To determine the safety and efficacy of IVIG and CP for COVID-19 and the different treatment effects between these two therapeutics to provide references for treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/6/22
|
Piscoya A, Parra Del Riego A, Cerna-Viacava R, et al. | PLoS One
Aim: To assess benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
6/2/22
|
Qu W, Wang Z, Engelberg-Cook E, et al. | Stem Cells Transl Med
Aim: To assess the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/31/22
|
Fernández-Lázaro D, Ortega CD, Sánchez-Serrano N, et al. | Pharmaceutics
Aim: To systematically analyze the evidence of the effect and safety of treatment with CP therapy using randomized controlled trials (RCTs) to confirm the usefulness of this intervention in hospitalized patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/31/22
|
Hosseini B, El Abd A, Ducharme FM | Nutrients
Aim: To evaluate the impact of vitamin D supplementation on COVID-19 related outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/31/22
|
Marin S, Val AM, Peligero MB, et al. | Pharmaceuticals
Aim: To assess and summarise the available literature on the early toxicity of CQ and HCQ alone or in combination with other drugs that have been used to treat COVID-19 in different clinical situations. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/31/22
|
Kim TH, Kang JW, Jeon SR, et al. | Front Med
Aim: To identify the overall usage prevalence of TCIM interventions for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/25/22
|
Ling RR, Ramanathan K, Sim JJL, et al. | Crit Care
Aim: To characterise changes in mortality over time and elucidate risk factors for poor outcomes in COVID-19 patients receiving ECMO. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/24/22
|
Pacheco JA, Molena KF, Martins CROG, et al. | Bull Natl Res Cent
Aim: To critically assess the clinical evidence on the use of photobiomodulation (PBMT) and antimicrobial photodynamic therapy (aPDT) for the treatment of oral lesions in patients infected with Sars-Cov-2.
CANDIDATE THERAPEUTICS
|
|
|
5/24/22
|
Lee TC, Murthy S, Del Corpo O, et al. | Clin Microbiol Infect
Aim: To evaluate the role of remdesivir for hospitalized inpatients as a function of oxygen requirements.
CANDIDATE THERAPEUTICS
|
|
|
5/24/22
|
Tabatabaeizadeh SA | Eur J Med Res
Aim: To evaluate the effect of zinc supplementation on COVID-19 mortality.
CANDIDATE THERAPEUTICS
|
|
|
5/23/22
|
Kesheh MM, Shavandi S, Haeri Moghaddam N, et al. | Virol J
Aim: To review the evidence on the effectiveness of herbal compounds against coronavirus family, which may have the potential in treating COVID19 infection.
CANDIDATE THERAPEUTICS
|
|
|
5/18/22
|
Lan SH, Lai CC, Chang SP, et al. | Expert Rev Clin Pharmacol
Aim: To investigate the clinical efficacy and safety of favipiravir for patients with mild-to-critical COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/16/22
|
Toro-Huamanchumo CJ, Benites-Meza JK, Mamani-García CS, et al. | J Clin Med
Aim: To assess the efficacy of colchicine in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/12/22
|
Moneer O, Daly G, Skydel JJ, et al. | BMJ
Aim: To systematically identify, match, and compare treatment effects and study demographics from individual or meta-analysed observational studies and randomized controlled trials (RCTs) evaluating the same covid-19 treatments, comparators, and outcomes.
CANDIDATE THERAPEUTICS
|
|
|
5/11/22
|
Kolahdouzan K, Chavoshi M, Bayani R, et al. | Int J Radiat Oncol Biol Phys
Aim: To review studies incorporating WLI for the treatment of COVID-19 pneumonia. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/26/22
|
Deng J, Heybati K, Ramaraju HB, et al. | Infection
Aim: To assess and compare the relative efficacy and safety of anti-SARS-CoV-2 antibody regimens for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/26/22
|
Conti V, Sellitto C, Torsiello M, et al. | JAMA Netw Open
Aim: To identify DDIs that led to adverse clinical outcomes and/or adverse drug reactions in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/26/22
|
Romeo FJ, Barbagelata L, Chiabrando JG, et al. | Am J Ther
Aim: To conduct an updated systematic review and meta-analysis of randomized clinical trials to assess a potential benefit of colchicine in hospitalized patients with COVID-19 infection. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/18/22
|
Sulakshana S, Nayak SS, Perumal S, et al. | Anesth Essays Res
Aim: To review the evidence on the occurance of heparin-induced thrombocytopenia in COVID-19
CANDIDATE THERAPEUTICS
|
|
|
4/18/22
|
Tasoudis PT, Arvaniti CK, Adamou AT, et al. | Eur J Intern Med
Aim: To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
4/14/22
|
Minkove SJ, Sun J, Li Y, et al. | Rev Med Virol
Aim: To analyse studies presenting the adjusted effects specifically of ICI therapy on either survival, a severe event, or need for hospitalisation in cancer patients presenting with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/14/22
|
Ulbrichtova R, Svihrova V, Svihra J | Int J Environ Res Public Health
Aim: To evaluate the prevalence of COVID-19 vaccination among medical students worldwide. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/14/22
|
Vieira AGDS, Pinto ACPN, Garcia BMSP, et al. | J Physiother
Aim: To review the evidence on the effectiveness and safety of telerehabilitation for people with COVID-19 and post-COVID-19 conditions. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/11/22
|
Edilgireeva LA, Sadulaeva TA, Zakharov VV, et al. | Zh Nevrol Psikhiatr Im S S Korsakova
Aim: To assess the effect of antiplatelet therapy on the risk of thrombotic complications and disease course in SARS-COV-2 infected patients.
CANDIDATE THERAPEUTICS
|
|
|
4/8/22
|
Fallah-Aliabadi S, Fatemi F, Heydari A, et al. | Public Health Nurs
Aim: To identify and categorize social vulnerability indicators in the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
4/7/22
|
Lee TC, Vigod S, Bortolussi-Courval É, et al. | JAMA Netw Open
Aim: To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/7/22
|
Bhuta S, Khokher W, Kesireddy N, et al. | Am J Ther
Aim: To investigate the efficacy of fluvoxamine in nonhospitalized patients with acute COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
4/7/22
|
Fadlalla M, Ahmed M, Ali M, et al. | Curr Pharmacol Rep
Aim: To review and summarize research of FDA-approved drugs repurposed against SARS-CoV-2 virus.
CANDIDATE THERAPEUTICS
|
|
|
4/7/22
|
Yasmin F, Najeeb H, Moeed A, et al. | PLoS One
Aim: To evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials.
CANDIDATE THERAPEUTICS
|
|
|
4/6/22
|
Bailey CJ, Gwilt M | Front Pharmacol
Aim: To review the clinical literature on clinical outcomes in metformin-treated subjects presenting with Covid-19.
CANDIDATE THERAPEUTICS
|
|
|
4/6/22
|
Rauniyar R, Mishra A, Kharel S, et al. | Can J Infect Dis Med Microbiol
Aim: To evaluate the optimal treatment using IVIG alone versus IVIG plus glucocorticoids.
CANDIDATE THERAPEUTICS
|
|
|
4/4/22
|
Mohanty RR, Biswa Mohan Padhy, Meher BR | J Pharm Pharm Sci
Aim: To determine the efficacy and safety of the pulse dose methyl prednisolone in management of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/4/22
|
Mazidimoradi A, Alemzadeh E, Alemzadeh E, et al. | Life Sci
Aim: To evaluate the effect of polyunsaturated fatty acids on the prognosis of Covid-19 disease.
CANDIDATE THERAPEUTICS
|
|
|
4/1/22
|
Yasuda H, Mayumi T, Okano H | Infection
Aim: To examine the effects of anticoagulant doses administered to patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/1/22
|
Kim DH, Kim SW, Kang M, et al. | Clin Otolaryngol
Aim: To assess the effect of topical steroids on acute-onset olfactory dysfunction in patients infected with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/31/22
|
Hong S, Wang H, Zhang Z, et al. | Steroids
Aim: To evaluate the efficacy and safety of methylprednisolone in the treatment of patients with COVID-19 compared with no corticosteroids therapy.
CANDIDATE THERAPEUTICS
|
|
|
3/30/22
|
Zheng W, Sun HL, Cai H, et al. | J Affect Disord
Aim: To evaluate the efficacy and safety of adjunctive antidepressants for COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/30/22
|
Yu SY, Koh DH, Choi M, et al. | Emerg Microbes Infect
Aim: To investigate the efficacy and safety of interleukin-6 (IL-6) receptor antagonists with standard care treatment in patients with coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/28/22
|
Beran A, Mhanna M, Srour O, et al. | Clin Nutr ESPEN
Aim: To provide a quantitative assessment of the clinical significance of micronutrient supplements in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/28/22
|
Bania A, Pitsikakis K, Mavrovounis G, et al. | J Pers Med
Aim: To summarize the most recent evidence regarding the therapeutic role of vitamin D on severe COVID-19 outcomes (length of hospital stay, mechanical ventilation, mortality) in adult populations. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/25/22
|
Beran A, Srour O, Malhas SE, et al. | Respir Care
Aim: To evaluate the effect of HFNC vs. NIV in COVID-19-related AHRF.
CANDIDATE THERAPEUTICS
|
|
|
3/25/22
|
He Y, Liu N, Zhuang X, et al. | Ther Adv Respir Dis
Aim: To compare the effectiveness and value of high-flow nasal cannula (HFNC) with noninvasive ventilation (NIV) for COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/25/22
|
Mutua V, Henry BM, Csefalvay CV, et al. | Acta Biomed
Aim: To explore the clinical benefits and safety of tocilizumab in addition to standard of care (SOC) in treating patients with coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/25/22
|
Helman SN, Adler J, Jafari A, et al. | Allergy Asthma Proc
Aim: To review the evidence on the medical and procedural treatment options for PVOD.
CANDIDATE THERAPEUTICS
|
|
|
3/24/22
|
Bitterman A, Martins CP, Cices A, et al. | JAMA Netw Open
Aim: To evaluate the association between regional prevalence of strongyloidiasis and ivermectin trial results for the outcome of mortality by testing the hypothesis that strongyloidiasis prevalence interacts with the RR of mortality.
CANDIDATE THERAPEUTICS
|
|
|
3/24/22
|
Jeon SR, Kang JW, Ang L, et al. | Integr Med Res
Aim: To create an evidence map which includes information for the CAM interventions according to what those interventions have strong evidence and those that need further testing.
CANDIDATE THERAPEUTICS
|
|
|
3/18/22
|
Glenardi G, Chriestya F, Oetoro BJ, et al. | Acute Crit Care
Aim: To investigate the efficacy of HFNC compared to NIV in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/18/22
|
Kamal L, Ramadan A, Farraj S, et al. | Saudi Pharm J
Aim: To review the evidence on molnupiravir safety and anti-viral activity.
CANDIDATE THERAPEUTICS
|
|
|
3/14/22
|
Argano C, Mallaci Bocchio R, Lo Monaco M, et al. | Int J Mol Sci
Aim: To assess the association between vitamin D supplementation and inflammatory markers in patients with diabetes; furthermore, vitamin D’s possible role in COVID-19 patients was assessed as well.
CANDIDATE THERAPEUTICS
|
|
|
3/14/22
|
Cao C, Gan X, Hu X, et al. | Aging
Aim: To evaluate the relationship between active immunotherapy and outcomes of cancer patients who had concurrent COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
3/14/22
|
Centeno-Cortez AK, Diaz-Chavez B, Santoyo-Saavedra DR, et al. | Rev Med Inst Mex Seguro Soc
Aim: To sustain with scientific evidence the importance of respiratory physiotherapy and its effects on post-acute COVID-19 adult patients.
CANDIDATE THERAPEUTICS
|
|
|
3/14/22
|
Ojo O, Ojo OO, Feng Q, et al. | Nutrients
Aim: To evaluate the effects of enteral nutrition in critically ill patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/11/22
|
Abdelazeem B, Awad AK, Elbadawy MA, et al. | Drug Discov Ther
Aim: To evaluate the effects of curcumin in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/10/22
|
Griesel M, Wagner C, Mikolajewska A, et al. | Cochrane Database Syst Rev
Aim: To assess whether inhaled corticosteroids are effective and safe in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/9/22
|
Sanghavi D, Bansal P, Kaur IP, et al. | Ann Med
Aim: To evaluate the role of colchicine on morbidity and mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/8/22
|
Yao J, Zhang Y, Wang XZ, et al. | Front Public Health
Aim: To investigate the efficacy of flavonoids in treating viral ARTIs.
CANDIDATE THERAPEUTICS
|
|
|
3/8/22
|
Liao ZM, Zhang ZM, Liu Q | Ren Fail
Aim: To determine whether hydroxychloroquine/chloroquine increases the risk of acute kidney injury (AKI) in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/7/22
|
Flumignan RL, Civile VT, Tinôco JDS, et al. | Cochrane Database Syst Rev
Aim: To assess the benefits and harms of anticoagulants versus active comparator, placebo or no intervention in people hospitalised with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/7/22
|
Zhang J, Chen C, Yang Y, et al. | Medicine
Aim: To investigate the effectiveness of tocilizumab in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/7/22
|
Hu Y, Kung J, Cave A, et al. | J Pharm Pharm Sci
Aim: To determine the clinical effects of Vitamin D serum concentration in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/4/22
|
Izcovich A, Siemieniuk RA, Bartoszko JJ, et al. | BMJ Open
Aim: To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/2/22
|
Kang X, Jin D, Jiang L, et al. | Chin Med
Aim: To evaluate the efficacy and explore the mechanisms of TCM for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/2/22
|
Kaka AS, MacDonald R, Linskens EJ, et al. | Ann Intern Med
Aim: To evaluate the effectiveness and harms of remdesivir for COVID-19. UPDATED VA ESP
CANDIDATE THERAPEUTICS
|
|
|
3/2/22
|
Pechlivanidou E, Vlachakis D, Tsarouhas K, et al. | Food Chem Toxicol
Aim: To summarize and describe human studies investigating the prognostic role of micronutrient status and the effects of micronutrient supplementation intervention in COVID-19 outcomes of adult patients.
CANDIDATE THERAPEUTICS
|
|
|
2/28/22
|
Jorda A, Kussmann M, Kolenchery N, et al. | Front Immunol
Aim: To evaluate whether the use of convalescent plasma is associated with improved clinical outcomes in patients with Covid-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/28/22
|
Ahmadi Hekmatikar AH, Ferreira Júnior JB, Shahrbanian S, et al. | Int J Environ Res Public Health
Aim: To evaluate the effect of resistance or aerobic exercises in post-COVID-19 patients after hospital discharge.
CANDIDATE THERAPEUTICS
|
|
|
2/28/22
|
Balboni E, Zagnoli F, Filippini T, et al. | J Trace Elem Med Biol
Aim: To review the evidence for possible effects of zinc or selenium on COVID-19, and therefore if there is any indication that increased intake of these trace elements is warranted and appropriate to prevent the current COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
2/23/22
|
Wang Z, Zhao S, Tang Y, et al. | Eur J Pediatr
Aim: To evaluate the efficacy and safety of using potential drugs: remdesivir and glucocorticoid in treating children and adolescents with COVID-19 and intravenous immunoglobulin (IVIG) in treating MIS-C. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/22/22
|
Galanis P, Vraka I, Siskou O, et al. | Prev Med
Aim: To estimate parents' willingness and refusal to vaccinate their children against the COVID-19, and to investigate the predictors for their decision. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/16/22
|
Christensen RE, Jafferany M | JAAD Int
Aim: To investigate the association between new-onset alopecia areata or the exacerbation of pre-existing alopecia areata following infection with SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
2/15/22
|
Tu J, Mo X, Zhang X, et al. | Expert Rev Respir Med
Aim: To assess the efficacy and safety of corticosteroids in COVID-19 patients compared with standard care or placebo. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/15/22
|
Zhang X, Shang L, Fan G, et al. | Front Med
Aim: To provide a comprehensive summary of current evidence for a better understanding of the efficacy and safety of JAK inhibitors for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/14/22
|
Yang P, Wang J, Zheng R, et al. | Heart Lung
Aim: To evaluate the clinical improvement and mortality risk of convalescent plasma treatment in patients with severe and critically ill COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/14/22
|
Koritala T, Pattan V, Tirupathi R, et al. | Infez Med
Aim: To summarize infection risk of IL inhibitors, with or without the use of corticosteroids, used to treat hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/14/22
|
Ao G, Li J, Yuan Y, et al. | Nutr Clin Pract
Aim: To compare the disease severity and mortality in patients with COVID-19 who promptly received IV-VC treatment vs those who did not.
CANDIDATE THERAPEUTICS
|
|
|
2/14/22
|
Dilokthornsakul W, Kosiyaporn R, Wuttipongwaragon R, et al. | J Integr Med
Aim: To review the mechanisms of propolis and honey against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and current evidence for the use of propolis and honey in COVID-19 prevention and treatment.
CANDIDATE THERAPEUTICS
|
|
|
2/11/22
|
Hsu CK, Chen CY, Chen WC, et al. | Int J Antimicrob Agents
Aim: To assess the impact of sofosbuvir-based treatment on the mortality of patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/11/22
|
Ji Y, Fang Y, Cheng B, et al. | Crit Care
Aim: To systematically appraise the existing COVID-19 studies examining the impact of ET on the primary outcomes of duration of IMV, duration of ICU stay, and overall reported mortality and secondary outcomes of ventilator-associated pneumonia (VAP), time from tracheostomy to ventilator weaning, and duration of sedation.
CANDIDATE THERAPEUTICS
|
|
|
2/11/22
|
Tanni SE, Silvinato A, Floriano I, et al. | J Bras Pneumol
Aim: To answer questions related to the use of remdesivir for the treatment of patients hospitalized with moderate to severe COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/9/22
|
Boppana TK, Mittal S, Madan K, et al. | Monaldi Arch Chest Dis
Aim: To estimate the effectiveness of tocilizumab in reduction of mortality due to COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/8/22
|
Shi S, Wang F, Yao H, et al. | Front Med
Aim: To evaluate the potential effect of CHM on immune related profile compared with routine treatment during COVID-19, and to investigate whether the clinical parameters were improved through the immunity profile based on randomized controlled trials (RCTs). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/8/22
|
Budi DS, Pratama NR, Wafa IA, et al. | Heliyon
Aim: To critically evaluate and summarize the latest evidence of remdesivir for COVID-19 in terms of its efficacy and safety profile among pregnant women. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/8/22
|
Wang Y, Zhu K, Dai R, et al. | Front Pharmacol
Aim: To evaluate the efficacy and safety of specific interleukin (IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 (at the edge of sepsis) patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/7/22
|
Ganesh A, Randall MD | Br J Clin Pharmacol
Aim: To investigate the effects of metformin on outcomes in patients with COVID-19 and DM. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/7/22
|
Wu H, Dai R, Wu X, et al. | Am J Chin Med
Aim: To evaluate the efficacy and safety of traditional Chinese medicine for COVID-19 treatment with a focus on the benefits of symptomatic relief and time-related indexes.
CANDIDATE THERAPEUTICS
|
|
|
2/4/22
|
Patoulias D, Doumas M | Endocrinol Metab
Aim: To review the evidence from observational studies addressing the risk of COVID-19 death among patients with type 2 diabetes mellitus on prior DPP-4 inhibitor treatment.
CANDIDATE THERAPEUTICS
|
|
|
2/2/22
|
Vegivinti CTR, Evanson KW, Lyons H, et al. | BMC Infect Dis
Aim: To review current evidence obtained from randomized clinical trials on the efficacy of antivirals for COVID-19 treatment.
CANDIDATE THERAPEUTICS
|
|
|
1/31/22
|
Varikasuvu SR, Thangappazham B, Vykunta A, et al. | Expert Rev Anti Infect Ther
Aim: To evaluate the use of vitamin D intervention on COVID-19 outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/31/22
|
Lin WT, Hung SH, Lai CC, et al. | J Med Virol
Aim: To assess the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for outpatients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/28/22
|
Lim PC, Wong KL, Rajah R, et al. | Daru
Aim: To collate studies investigating the use of tocilizumab and corticosteroids particularly dexamethasone and methylprednisolone in COVID-19 treatment and sought for summative evidence for their efficacy in treating the disease.
CANDIDATE THERAPEUTICS
|
|
|
1/27/22
|
Zein AFMZ, Raffaello WM | Diabetes Metab Syndr
Aim: To evaluate the latest evidence on the association between colchicine and mortality in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/27/22
|
Boppana TK, Mittal S, Madan K, et al. | Monaldi Arch Chest Dis
Aim: To estimate the effectiveness of steroid administration in mortality reduction due to COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Singh AK, Singh A, Singh R, et al. | Diabetes Metab Syndr
Aim: To conduct an update on our previous systematic review to provide practical clinical guideline for using molnupiravir in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Mohanty RR, Das S, Padhy BM, et al. | J Assoc Physicians India
Aim: To address whether choice of systemic corticosteroid significantly influences the clinical outcome of COVID 19 patients.
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, et al. | Nutrients
Aim: To investigate the efficacy of supplemental curcumin treatment on clinical outcomes and inflammation-related biomarker profiles in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Focosi D, Franchini M, Tuccori M, et al. | Vaccines
Aim: To evaluate the efficacy and safety of polyclonal intravenous immunoglobulin (IVIG) therapy in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Latif J, Elizabeth Weekes C, Julian A, et al. | Clin Nutr ESPEN
Aim: To evaluate what evidence is available to inform evidence-based decision making on the nutritional care of patients hospitalised with COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
1/24/22
|
Korang SK, von Rohden E, Veroniki AA, et al. | PLoS One
Aim: To assess the effectiveness and safety of COVID-19 vaccines through analyses of all currently available randomized clinical trials. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/19/22
|
Peng J, She X, Mei H, et al. | Aging
Aim: To explore and summarize the association between treatment with tocilizumab and clinical outcomes in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
1/19/22
|
Haas JW, Bender FL, Ballou S, et al. | JAMA Netw Open
Aim: To compare the frequencies of AEs reported in the placebo groups of COVID-19 vaccine trials with those reported in the vaccine groups. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/18/22
|
Zhang S, Yang Z, Chen ZL, et al. | Evid Based Complement Alternat Med
Aim: To systematically evaluate the efficacy and safety of TMTP for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/18/22
|
Kumar A, Rai A, Khan MS, et al. | J Tradit Complement Med
Aim: To review the evidence on the efficacy and side effects of herbal medicine supplementation with Western medicine in the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/17/22
|
Lan SH, Lee HZ, Chao CM, et al. | J Med Virol
Aim: To investigate the effect of melatonin on clinical outcomes in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/12/22
|
Reis S, Popp M, Schmid B, et al. | J Clin Med
Aim: To determine the safety and efficacy of intensified anticoagulation with intermediate or therapeutic doses compared to standard-dose thromboprophylaxis in hospitalised patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/11/22
|
Xavier-Santos D, Padilha M, Fabiano GA, et al. | Trends Food Sci Technol
Aim: To provide insights and perspectives for the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention/treatment and/or modulation of the microbiota in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
1/7/22
|
Yu R, Zhang S, Zhao D, et al. | Expert Rev Mol Med
Aim: To compare the outcomes of COVID-19 patients treated with Integrated Chinese with Western Medicine versus Western Medicine alone.
CANDIDATE THERAPEUTICS
|
|
|
1/4/22
|
Sholzberg M, da Costa BR, Tang GH, et al. | Res Pract Thromb Haemost
Aim: To determine the effects of therapeutic heparin in hospitalized patients with COVID?19.
CANDIDATE THERAPEUTICS
|
|
|
1/3/22
|
Kow CS, Lee LH, Ramachandram DS, et al. | Immun Inflamm Dis
Aim: To investigate the effect of colchicine in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/31/21
|
Ge J, Ma Y, Wu Z, et al. | Medicine
Aim: To better inform efforts to treat and control the current outbreak with effective anticoagulant treatment strategies for coronavirus disease 2019 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/30/21
|
Chiu L, Lo C, Shen M, et al. | PLoS One
Aim: To report on the state of the current literature on the use of colchicine in COVID-19 and to investigate the reported clinical outcomes in COVID-19 patients by colchicine usage. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/30/21
|
Baez-Ferrer N, Bompart-Cairos A, Lopez-Rial D, et al. | Cardiomyopathy and Heart Failure
Aim: To analyze the mortality of patients with ARDS due to SARS-CoV-2 who required ECMO.
CANDIDATE THERAPEUTICS
|
|
|
12/29/21
|
Akbari A, Razmi M, Sedaghat A, et al. | Expert Rev Anti Infect Ther
Aim: To assess the comparative effectiveness of pharmacological agents in published RCTs.
CANDIDATE THERAPEUTICS
|
|
|
12/29/21
|
Ma KS, Lee CC, Liu KJ, et al. | Pathogens
Aim: To evaluate strategies for augmentation of host immunity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.
CANDIDATE THERAPEUTICS
|
|
|
12/29/21
|
Tentolouris N, Samakidou G, Eleftheriadou I, et al. | Diabetes Metab Res Rev
Aim: To investigate the effect of vitamin D supplementation on mortality and admission to intensive care unit (ICU) of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
12/27/21
|
Zein AFMZ, Raffaello WM | Prim Care Diabetes
Aim: To synthesize the latest evidence on the effect of dipeptidyl peptidase-4 (DPP-IV) inhibitor in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/27/21
|
Golpour M, Mousavi T, Alimohammadi M, et al. | Int J Immunopathl Pharmacol
Aim: To evaluate the efficacy of Colchicine in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/27/21
|
Kwak SG, Choo YJ, Chang MC | Complement Ther Med
Aim: To investigate the therapeutic effect of high-dose intravenous vitamin C (HDIVC) in patients with coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
12/23/21
|
Izcovich A, Peiris S, Ragusa M, et al. | J Clin Epidemiol
Aim: To summarize the best available evidence on ivermectin for prevention and treatment of COVID-19 patients and explore potential explanations for heterogeneity in RCTs results with focus on studies methodological limitations.
CANDIDATE THERAPEUTICS
|
|
|
12/23/21
|
Agarwal N, Mishra S, Ayub A | J Family Med Prim Care
Aim: To find out the impact on the discharge status from hospital of the patients receiving convalescent plasma therapy. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/23/21
|
Ebrahimi Chaharom F, Pourafkari L, Ebrahimi Chaharom AA, et al. | Pulm Pharmacol Ther
Aim: To evaluate the impact of corticosteroids on the mortality rate, HLOS, ICU admission, intubation, and mechanical ventilation in Covid-19 patients with severe pneumonia.
CANDIDATE THERAPEUTICS
|
|
|
12/22/21
|
Guo J, Qin Z, Lau NC, et al. | Am J Chin Med
Aim: To evaluate the efficacy and safety of Chinese medicine (CM) against COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/17/21
|
Arabpour E, Khoshdel S, Tabatabaie N, et al. | Front Med
Aim: To evaluate the safety and efficacy of stem cells in treating patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/17/21
|
Crichton ML, Goeminne PC, Tuand K, et al. | Eur Respir Rev
Aim: To show the impact of different COVID-19 therapeutics on mortality in hospitalised patients.
CANDIDATE THERAPEUTICS
|
|
|
12/16/21
|
Bertini P, Guarracino F, Falcone M, et al. | J Cardiothorac Vasc Anesth
Aim: To summarize evidence from all available studies to assess the mortality of patients with COVID-19 treated with VV ECMO. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/16/21
|
Raji H, Arjmand B, Rahim F | Adv Exp Med Biol
Aim: To evaluate the probable effect of the PBM therapy on the lung inflammation or ARDS and accelerate the regeneration of the damaged tissue.
CANDIDATE THERAPEUTICS
|
|
|
12/14/21
|
Khan S, Hasan SS, Bond SE, et al. | Expert Rev Anti Infect Ther
Aim: To review the evidence on the consumption of antimicrobials by patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/13/21
|
Kollias A, Kyriakoulis KG, Trontzas IP, et al. | J Clin Med
Aim: To assess the risk of in-hospital mortality in hospitalized patients with COVID-19 receiving high (intermediate or therapeutic) versus prophylactic doses of thromboprophylaxis. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/13/21
|
Dissanayake HA, de Silva NL, Sumanatilleke M, et al. | J Clin Endocrinol Metab
Aim: To determine the association between vitamin D deficiency/insufficiency and susceptibility to COVID-19, its severity, mortality and role of vitamin D in its treatment.
CANDIDATE THERAPEUTICS
|
|
|
12/13/21
|
Kokkotis G, Kitsou K, Xynogalas I, et al. | Aliment Pharmacol Ther
Aim: To investigate the impact of anti-TNF treatments on the clinical outcomes of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
12/8/21
|
Li Y, Wei Z, Ma X, et al. | Curr Stem Cell Res
Aim: To assess the safety and efficacy of stem cell therapy for COVID-19 by providing references for subsequent clinical treatments and trials.
CANDIDATE THERAPEUTICS
|
|
|
12/7/21
|
Sarkar S, Khanna P, Singh AK | Indian J Crit Care Med
Aim: To analyze the current evidence of the efficacy and safety of convalescent plasma therapy in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
12/6/21
|
De-Miguel-Balsa E, Estevan-Ortega R, Sempere-Selva MT, et al. | Eur Rev Med Pharmacol Sci
Aim: To assess the effectiveness of colchicine, compared with standard of care, for reducing mortality, admission to intensive care, and use of mechanical ventilation.
CANDIDATE THERAPEUTICS
|
|
|
12/2/21
|
Qomara WF, Primanissa DN, Amalia SH, et al. | Int J Gen Med
Aim: To summarize the clinical effectiveness and safety of remdesivir, favipiravir, and lopinavir/ritonavir on COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/1/21
|
Lin Z, Niu J, Xu Y, et al. | J Med Virol
Aim: To determine the clinical efficacy and adverse events of baricitnib in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/29/21
|
Torres Neto L, Monteiro MLG, Galvan D, et al. | Pharmaceuticals
Aim: To identify the most promising EO compounds and potential EO sources against COVID-19 based on their affinity by target proteins, drug-likeness, bioactivity score, and ADME/T.
CANDIDATE THERAPEUTICS
|
|
|
11/29/21
|
Vargas M, Marra A, Buonanno P, et al. | J Clin Med
Aim: To investigate the impact of corticosteroids on mortality in ARDS in both COVID-19 and non-COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
11/29/21
|
Sagris D, Florentin M, Tasoudis P, et al. | J Clin Med
Aim: To investigate the potential beneficial effect of immunomodulation therapy on the thromboembolic risk in hospitalized COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/29/21
|
Yu M, Wang DC, Li S, et al. | J Med Virol
Aim: To systematically evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir (LPV/r) in the treatment of coronavirus disease 2019(COVID-19) using a meta-analysis method.
CANDIDATE THERAPEUTICS
|
|
|
11/23/21
|
Axfors C, Janiaud P, Schmitt AM, et al. | BMC Infect Dis
Aim: To assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/22/21
|
Smith N, Mitton C, Donaldson M, et al. | SPOR
Aim: To review the evidence on rapid diagnostic testing (RDT) for COVID-19 as a tool to limit school closures.
CANDIDATE THERAPEUTICS
|
|
|
11/19/21
|
Ayerbe L, Risco-Risco C, Forgnone I, et al. | J Antimicrob Chemother
Aim: To summarize the available evidence to date on the beneficial and adverse effects of azithromycin in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/18/21
|
Amer YS, Titi MA, Godah MW, et al. | J Clin Epidemiol
Aim: To systematically identify and critically assess the clinical practice guidelines (CPGs) for the management of critically ill patients with COVID-19 with the AGREE II instrument. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/17/21
|
Ling RR, Sim JJL, Tan FL, et al. | Transfus Med Rev
Aim: To investigate whether convalescent plasma is futile in reducing mortality in patients hospitalized with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/15/21
|
Arco-Torres A, Cortés-Martín J, Tovar-Gálvez MI, et al. | J Clin Med
Aim: To compile existing knowledge about currently available drug treatments for COVID-19 in pregnant women. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/15/21
|
Maraolo AE, Crispo A, Piezzo M, et al. | J Clin Med
Aim: To compare the use of TCZ with placebo or standard of care (SoC), for the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/15/21
|
Giesbers S, Goh E, Kew T, et al. | ur J Obstet Gynecol Reprod Biol
Aim: To review the evidence on the effects of pharmacological and non-pharmacological interventions for COVID-19 on maternal and neonatal pregnancy outcomes.
CANDIDATE THERAPEUTICS
|
|
|
11/11/21
|
Kow CS, Ramachandram DS, Hasan SS | Hypertens Res
Aim: To determine the overall effect of the preadmission/prediagnosis use of calcium channel blockers (CCBs) on the clinical outcomes in hypertensive patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/11/21
|
Beran A, Mhanna M, Srour O, et al. | Respir Care
Aim: To evaluate the effectiveness of APP to improve the clinical outcomes in non-intubated subjects with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/11/21
|
Ngamprasertchai T, Kajeekul R, Sivakorn C, et al. | Infect Dis Ther
Aim: To rank immunomodulators in the treatment of COVID-19 according to their efficacy and safety. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/11/21
|
Kannapadi NV, Jami M, Premraj L, et al. | Heart Lung Circ
Aim: To characterise neurological events during ECMO support in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
11/11/21
|
Wijaya I, Andhika R, Huang I, et al. | Clin Epidemiol Glob Health
Aim: To assess the effect of aspirin on the outcome in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/10/21
|
Zanirati G, Provenzi L, Libermann LL, et al. | NPJ Regen Med
Aim: To investigate different types of stem cells as treatments for COVID-19 and ARDS to evaluate the safety and potential efficacy of cell therapy. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/9/21
|
Chen WC, Hsu CK, Chen CY, et al. | Expert Rev Anti Infect Ther
Aim: To investigate the efficacy of interferon (IFN)-beta-containing regimens in treating patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/8/21
|
Chiu L, Shen M, Lo CH, et al. | PLoS One
Aim: To summarize the current literature and report clinical outcomes on the use of famotidine for treatment of hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/8/21
|
Singh AK, Singh A, Singh R, et al. | Diabetes Metab Syndr
Aim: To find out the efficacy and safety of molnupiravir in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/8/21
|
Rawat D, Roy A, Maitra S, et al. | Diabetes Metab Syndr
Aim: To find out the impact of Vitamin-C administration on major clinical outcomes (mortality, ICU admission, hospital stay, mechanical ventilation) in patients diagnosed with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/5/21
|
Chilkoti GT, Mohta M, Saxena AK, et al. | Indian J Crit Care Med
Aim: To investigate the efficacy of prone positioning (PP) in the management of coronavirus disease-2019 (COVID-19) pneumonia in various setups, with various modes of oxygen therapy and its optimal duration.
CANDIDATE THERAPEUTICS
|
|
|
11/5/21
|
Parashar S, Karthik AR, Gupta R, et al. | Indian J Crit Care Med
Aim: To systemically appraise and summarize the available literature regarding the role of awake proning in the management of COVID-19 novel coronavirus pneumonia. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/4/21
|
Malgie J, Schoones JW, Zeegers MP, et al. | Sci Rep
Aim: To review the evidence on the effectiveness of IL-6 receptor antagonists on patients hospitalized with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/4/21
|
Quincho-Lopez A, Benites-Ibarra CA, Hilario-Gomez MM, et al. | PLoS One
Aim: To assess the prevalence of self-medication for the prevention or management of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/4/21
|
Hunter J, Arentz S, Goldenberg J, et al. | BMJ Open
Aim: To evaluate the benefits and risks of zinc formulations compared with controls for prevention or treatment of acute viral respiratory tract infections (RTIs) in adults.
CANDIDATE THERAPEUTICS
|
|
|
11/2/21
|
Kow CS, Javed A, Ramachandram D, et al. | Expert Rev Anti Infect Ther
Aim: To review the evidence on the clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/2/21
|
Chamlagain R, Shah S, Sharma Paudel B, et al. | Interdiscip Perspect Infect Dis
Aim: To assess the role of sarilumab in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/2/21
|
Antony Leo Asser P, Soundararajan K | Work
Aim: To synthesize physiotherapy-related articles to COVID-19 and summarize their efficacious highlights.
CANDIDATE THERAPEUTICS
|
|
|
11/1/21
|
Astasio-Picado A, del Rocío Sánchez-Sánchez M | Appl Sci
Aim: To evaluate the effectiveness of the prone position in patients with acute respiratory distress syndrome as a consequence of the COVID-19 disease who are mechanically ventilated and admitted to the intensive care unit.
CANDIDATE THERAPEUTICS
|
|
|
11/1/21
|
Vela D, Vela-Gaxha Z, Rexhepi M, et al. | Br J Clin Pharmacol
Aim: To evaluate the efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/1/21
|
Alunno A, Najm A, Mariette X, et al. | RMD Open
Aim: To update the EULAR 2020 systematic literature review (SLR) on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
10/29/21
|
Sarwar M, Ali Z, Fatima M, et al. | J Clin Lab Anal
Aim: To determine the efficacy of colchicine in optimizing inflammatory hematological biomarker levels among COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
10/28/21
|
Belletti A, Campochiaro C, Marmiere M, et al. | Ann Intensive Care
Aim: To review the evidence on the use IL-6 inhibitors to treat COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/26/21
|
Shahsavarinia K, Ghojazadeh M, Ghabousian A, et al. | Anesth Pain Med
Aim: To investigate the clinical efficacy and cardiac toxicity of hydroxychloroquine or chloroquine with or without azithromycin in the setting of COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
10/25/21
|
Borsche L, Glauner B, von Mendel J | Nutrients
Aim: To collect further evidence on whether low D3 is caused by the infection or if deficiency negatively affects immune defense.
CANDIDATE THERAPEUTICS
|
|
|
10/25/21
|
Kumar S, Saurabh MK, Narasimha VL, et al. | Clin Drug Invest
Aim: To determine the efficacy of interferon-beta among moderate-to-severe COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/25/21
|
Kaul R, Paul P, Kumar S, et al. | Int J Mol Sci
Aim: To analyze the effects of flavonoids on various key SARS-CoV-2 targets.
CANDIDATE THERAPEUTICS
|
|
|
10/22/21
|
Popp M, Stegemann M, Riemer M, et al. | Cochrane Database Syst Rev
Aim: To assess the efficacy and safety of antibiotics compared to each other, no treatment, standard of care alone, placebo, or any other active intervention with proven efficacy for treatment of COVID-19 outpatients and inpatients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/20/21
|
Mikolajewska A, Fischer AL, Piechotta V, et al. | Cochrane Database Syst Rev
Aim: To assess the effectiveness and safety of Colchicine as a treatment option for COVID-19 in comparison to an active comparator, placebo, or standard care alone in any setting.
CANDIDATE THERAPEUTICS
|
|
|
10/20/21
|
Landolf KM, Lemieux SM, Rose C, et al. | Pharmacotherapy
Aim: To comprehensively evaluate the literature surrounding corticosteroid use in ARDS (non-COVID-19 and COVID-19) in addition to a narrative review of clinical considerations of corticosteroid use in these patient populations.
CANDIDATE THERAPEUTICS
|
|
|
10/18/21
|
Li J, Liao X, Zhou Y, et al. | BMC Infect Dis
Aim: To evaluate this potential effect from glucocorticoids treatment for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/15/21
|
Ferreto LED, Bortoloti DS, Fortes PCN, et al. | Sao Paulo Med J
Aim: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
10/15/21
|
Cao H, Ming L, Chen L, et al. | Front Med
Aim: To evaluate the clinical efficacy and safety of CCP for the COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/14/21
|
Kyriakoulis KG, Kollias A, Poulakou G, et al. | J Clin Med
Aim: To review the impact of anakinra on the outcomes of hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/14/21
|
Szarpak L, Filipiak KJ, Gasecka A, et al. | Cardiol J
Aim: To summarize the studies published to date regarding the vitamin D supplementation to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Gandhi G, Thimmappa L, Upadhya N, et al. | Int J Dent Hyg
Aim: To find the efficacy of oral rinses on virucidal property against n-coronavirus (in vivo studies).
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Sanfilippo F, Martucci G, La Via L, et al. | Artif Organs
Aim: To summarize the evidence regarding HP therapy in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Ge L, Zhu H, Wang Q, et al. | J Evid Based Med
Aim: To develop a living evidence-based guideline of integrating Chinese and western medicine for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Vlieg-Boerstra B, de Jong N, Meyer R, et al. | Allergy
Aim: To evaluate the evidence for prevention of any RTI in the general population considered healthy through supplementation with nutrients that already have a recognized role in immune function.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Quiros JR, Ross-Comptis J, Hathaway D 3rd, et al. | Infect Chemother
Aim: To examine the efficacy and tolerability of ruxolitinib for adult COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Debeuf R, Swinnen E, Plattiau T, et al. | J Rehabil Med
Aim: To summarize the effects of physical therapy in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
10/12/21
|
Wu X, Li W, Qin Z, et al. | Medicine
Aim: To evaluate the efficacy and safety of TCM assisted in conventional treatment in the treatment of mild and common COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/8/21
|
Vaughan M, Trott M, Sapkota R, et al. | J Hum Nutr Diet
Aim: To review the literature examining the changes in 25(OH)D in different types of vitamin D supplementation from randomised controlled trials in this population.
CANDIDATE THERAPEUTICS
|
|
|
10/7/21
|
Arentz S, Hunter J, Khamba B, et al. | Integr Med Res
Aim: To evaluate the effects of honeybee products compared to controls for the prevention, duration, severity, and recovery of acute viral respiratory tract infections (RTIs), including SARS-CoV-2, in adults and children.
CANDIDATE THERAPEUTICS
|
|
|
10/6/21
|
Kaya MO, Pamukçu E, Yakar B | Epidemiol Health
Aim: To indicate the possible effect of low serum vitamin D (25(OH)D<20 ng/mL or 50nmol/L) on the Covid-19 infection and outcomes.
CANDIDATE THERAPEUTICS
|
|
|
10/5/21
|
Du XQ, Shi LP, Cao WF, et al. | Front Pharmacol
Aim: To critically evaluate the effectiveness and safety of honeysuckle for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/5/21
|
Kyriakopoulos C, Ntritsos G, Gogali A, et al. | Respirology
Aim: To evaluate the efficacy of tocilizumab in the management of hospitalized COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/4/21
|
Santenna C, Vidyasagar K, Amarneni KC, et al. | Ther Adv Drug Saf
Aim: To quantify the safety and tolerability of remdesivir, based on safety outcome findings from randomized controlled trials, observational studies and case reports of remdesivir in coronavirus disease 2019 (COVID-19) patients.
CANDIDATE THERAPEUTICS
|
|
|
9/30/21
|
Snow TAC, Saleem N, Ambler G, et al. | Br J Anaesth
Aim: To review the evidence on the use of convalescent plasma in the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/30/21
|
Cruciani M, Pati I, Masiello F, et al. | Diagnostics
Aim: To review the evidence on the use of ivermectin for the treatment and prophylaxis of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/30/21
|
Cardwell K, O Murchu E, Byrne P, et al. | Rev Med Virol
Aim: To determine the effectiveness of pharmacological interventions (excluding vaccines) to prevent coronavirus disease 2019 (Covid-19) or reduce the severity of disease.
CANDIDATE THERAPEUTICS
|
|
|
9/30/21
|
Franchini M, Corsini F, Focosi D, et al. | Diagnostics
Aim: To summarize the evidence from the available systematic reviews on the efficacy and safety of CP in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/28/21
|
Deng J, Zhou F, Ali S, et al. | QJM
Aim: To assess the efficacy and safety of ivermectin for treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/28/21
|
Vahedian-Azimi A, Mohammadi SM, Banach M, et al. | Biomed Res Int
Aim: To compare statin use on ICU admission, tracheal intubation, and death outcomes in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/27/21
|
Rubio-Rivas M, Forero CG, Mora-Luján JM, et al. | Pharmacotherapy
Aim: To summarize evidence about the effect of TCZ to treat severe COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/27/21
|
Peng J, Fu M, Mei H, et al. | Rev Med Virol
Aim: To explore the efficacy and safety of immunosuppressants therapy for COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/27/21
|
Gupta S, Padappayil RP, Bansal A, et al. | J Investig Med
Aim: To evaluate the effectiveness of tocilizumab in hospitalized patients with COVID-19 not requiring mechanical ventilation.
CANDIDATE THERAPEUTICS
|
|
|
9/23/21
|
Boet S, Etherington C, Djainai G, et al. | Diving Hyperb Med
Aim: To explore the potential effectiveness and safety of HBOT for treating patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/21/21
|
Giossi R, Menichelli D, Pani A, et al. | Front Pharmacol
Aim: To evaluate the effectiveness of heparin compared to no anticoagulant treatment in reducing overall mortality. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/21/21
|
Limen RY, Sedono R, Sugiarto A, | Expert Rev Anti Infect Ther
Aim: To analyze the efficacy of JAK-inhibitors to ameliorate the outcomes of Covid-19 sufferer.
CANDIDATE THERAPEUTICS
|
|
|
9/20/21
|
Zuo L, Ao G, Wang Y, et al. | J Infect
Aim: To investigate the efficacy of BAM in COVID?19.
CANDIDATE THERAPEUTICS
|
|
|
9/17/21
|
Wang Y, Greenhalgh T, Wardle J, et al. | J Eval Clin Pract
Aim: To evaluate the evidence behind claims that Chinese Herbal Medicine is an effective treatment for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/16/21
|
Piscoya A, Ng-Sueng LF, Parra Del Riego A, et al. | Arch Med Sci
Aim: To review the benefits and harms of convalescent plasma (CP) in hospitalized COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/15/21
|
Hu H, Ji Z, Feng C, et al. | Integr Med Res
Aim: To analyze the innovativeness and rigorousness of the SR protocols and make recommendations for the design and implementation of future SRs on TCM for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/15/21
|
Ortega-Paz L, Galli M, Capodanno D, et al. | Eur Heart J Cardiovasc Pharmacother
Aim: To review the evidence on the clinical impact of different prophylactic anticoagulation regimens among hospitalized patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/13/21
|
Razzack AA, Hassan SA, Pasya SKR, et al. | Infect Chemother
Aim: To review the evidence on the effectiveness of remdesivir in critically ill coronavirus disease 2019 (COVID-19) patients.
CANDIDATE THERAPEUTICS
|
|
|
9/13/21
|
Mahroum N, Watad A, Bridgewood C, et al. | Int J Environ Res Public Health
Aim: To investigate whether tocilizumab therapy directed against severe COVID-19 improved survival. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/9/21
|
Li H, Yan B, Gao R, et al. | Int Immunopharmacol
Aim: To assess the effects of corticosteroid therapy for patients with severe coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
9/9/21
|
Li Y, Yang X, Yan P, et al. | Front Med
Aim: To explore the impact of metformin use on COVID-19 mortality and other patient-important outcomes across various populations and studies. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/9/21
|
Campbell C, Andersson MI, Ansari MA, et al. | Front Med
Aim: To collate data for HBV and TB reactivation, and for complications of active HCV infection.
CANDIDATE THERAPEUTICS
|
|
|
9/9/21
|
Chaudhry MW, Zubair SM, Zubairi ABS, et al. | Adv Respir Med
Aim: To review the evidence on the effectiveness of ivermectin in hospitalized COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/9/21
|
Goudarzi S, Esmaeeli S, Valencia JD, et al. | Neurologist
Aim: To recapitulate the available treatments for COVID-19–related GBS and to provide a summary of clinical management strategies for this complication.
CANDIDATE THERAPEUTICS
|
|
|
9/8/21
|
Martins-Filho PR, Ferreira LC, Heimfarth L, et al. | Lancet Reg Health Am
Aim: To synthesize the best evidence on the efficacy and safety of HCQ as pre-and post-exposure prophylaxis and treatment of non-hospitalized and hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/3/21
|
Bryant A, Lawrie TA, Dowswell T, et al. | Am J Ther
Aim: To assess the efficacy of ivermectin treatment among people with covid-19 infection and as a prophylaxis among people at higher risk of COVID-19 infection. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/1/21
|
Aucoin M, Cardozo V, McLaren MD, et al. | Metab Open
Aim: To identify all research that has assessed changes in levels of cytokines relevant to cytokine storm in response to administration of Echinacea supplementation.
CANDIDATE THERAPEUTICS
|
|
|
8/31/21
|
Konwar M, Maurya M, Thatte UM, et al. | Curr Rev Clin Exp Pharmacol
Aim: To analyze the safety data of HCQ against placebo and active treatment in various disease conditions.
CANDIDATE THERAPEUTICS
|
|
|
8/31/21
|
Wang Q, Zhu H, Li M, et al. | Front Pharmacol
Aim: To evaluate the efficacy and safety of QFPD in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/31/21
|
Cuevas-Gonzalez MV, Garcia-Perez Á, Gonzalez-Aragon Pineda ÁE, et al. | Biomed Res Int
Aim: To evaluate the role of stem cells against SARS-CoV-2 and COVID-19 in order to identify their potential as a study model and a possible therapeutic source against tissue damage caused by SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
8/30/21
|
Abu-Rub LI, Abdelrahman HA, Johar AA, et al. | Antibiotics
Aim: To evaluate the prevalence of antibiotic prescribing in patients admitted to ICUs with SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
8/30/21
|
Gil Martínez V, Avedillo Salas A, Santander Ballestín S | Pharmaceuticals
Aim: To summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.
CANDIDATE THERAPEUTICS
|
|
|
8/30/21
|
Lien CH, Lee MD, Weng SL, et al. | Life
Aim: To investigate the effects of colchicine in treating patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/30/21
|
Krzych ?J, Putowski Z, Czok M, et al. | Viruses
Aim: To investigate a possible role of TPE in severe COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/26/21
|
Banerjee S, Mahapatra AK | Rev Recent Clin Trials
Aim: To review the evidence on the use of tocilizumab for the treatment for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/23/21
|
Du X, Shi L, Cao W, et al. | PLoS One
Aim: To evaluate the add-on effect of CHM in the treatment of mild to moderate COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/23/21
|
Andreas M, Piechotta V, Skoetz N, et al. | Cochrane Database Syst Rev
Aim: To assess the efficacy and safety of pharmacological and non-pharmacological interventions for palliative symptom control in individuals with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/23/21
|
Wang J, Shi P, Chen D, et al. | Stem Cells Dev
Aim: To review the evidence on the safety and effectiveness of MSCs in the treatment of COVID-19-associated pneumonia patients
CANDIDATE THERAPEUTICS
|
|
|
8/23/21
|
Oliaei S, SeyedAlinaghi S, Mehrtak M, et al. | Eur J Med Res
Aim: To systematically review the studies discussing hyperbaric oxygen therapy (HBOT) to examine its reported efficacy and adverse events in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/20/21
|
Hariyanto TI, Putri C, Hananto JE, et al. | J Psychiatr Res
Aim: To explore the potential association between delirium and poor outcomes from COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/18/21
|
Tadakamadla J, Boccalari E, Rathore V, et al. | J Infect Public Health
Aim: To evaluate the evidence on the efficacy of mouth rinses on SARS-CoV-2 from in vitro studies.
CANDIDATE THERAPEUTICS
|
|
|
8/17/21
|
Ridjab DA, Ivan I, Budiman F, et al. | Medicine
Aim: To evaluate risk of PR prolongation, QRS widening, and QT prolongation from lopinavir, ritonavir, atazanavir, and saquinavir.
CANDIDATE THERAPEUTICS
|
|
|
8/17/21
|
Kyriazopoulou E, Huet T, Cavalli G, et al. | Lancet Rheumatol
Aim: To assess the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/17/21
|
Wagner C, Griesel M, Mikolajewska A, et al. | Cochrane Database Syst Rev
Aim: To assess whether systemic corticosteroids are effective and safe in the treatment of people with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/17/21
|
Li F, Jiang Y, Yue B, et al. | Medicine
Aim: To evaluate the supportive effects of frequently used traditional Chinese medicine (TCM) for the treatment of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
8/16/21
|
Zinellu A, Mangoni AA | J Nephrol
Aim: To review the evidence on the effectiveness of serum cystatin C in COVID-19 in treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/16/21
|
Cui Y, Sun Y, Sun J, et al. | Infect Dis Ther
Aim: To explore the beneficial effect of corticosteroids, particularly in pulse methylprednisolone use in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/12/21
|
Kloypan C, Saesong M, Sangsuemoon J, et al. | Eur J Clin Invest
Aim: To investigate the efficacy of CP vs standard treatment/non-CP on clinical outcomes in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/12/21
|
Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca A, et al. |
Aim: To examine the effect of statins use on mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/10/21
|
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. | JAMA
Aim: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/9/21
|
Conti V, Corbi G, Sellitto C, et al. | J Pers Med
Aim: To review and assess the effectiveness of TCZ in reducing the mortality rate in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/5/21
|
Chen C, Chen W, Hsu C, et al. | Int Immunopharmacol
Aim: To investigate the clinical efficacy and safety of Janus kinase (JAK) inhibitors for COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/5/21
|
Özlü?en B, Kozan ?, Akcan RE, et al. | Eur J Clin Microbiol Infect Dis
Aim: To review the evidence on the effectiveness of Favipiravir on the fatality and the requirement of mechanical ventilation for the treatment of moderate to severe COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/5/21
|
Ansems K, Grundeis F, Dahms K, et al. | Cochrane Database Syst Rev
Aim: To assess the effects of remdesivir compared to placebo or standard care alone on clinical outcomes in hospitalised patients with SARS?CoV?2 infection.
CANDIDATE THERAPEUTICS
|
|
|
8/5/21
|
Sahu AK, Mathew R, Bhat R, et al. | QJM
Aim: To assess effect of steroids in mild COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/4/21
|
Jiang L, Li Y, Du H, et al. | Front Med
Aim: To clarify whether hospitalized patients with COVID-19 benefit from anticoagulation therapy (including both therapeutic– and prophylactic–dose anticoagulation therapy). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/4/21
|
Amani B, Amani B, Zareei S, et al. | Immun Inflamm Dis
Aim: To provide the latest evidence on arbidol's efficacy and safety compared with other therapeutic agents in COVID?19 treatment. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/4/21
|
Kow CS, Hasan SS | Am J Cardiovasc Drugs
Aim: To summarize the existing evidence on the effect of statins on the clinical outcomes of patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/3/21
|
Abate SM, Mantefardo B, Nega S, et al. | Ann Med Surg
Aim: To determine the prevalence, determinants, and outcomes of acute myocardial injury. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/3/21
|
Yuwono Soeroto A, Purwiga A, Alam A, et al. | Eur Rev Med Pharmacol Sci
Aim: To investigate the role of Convalescent Plasma (CP) in reducing mortality of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Okoli G, Rabbani R, Al-Juboori A, et al. | Expert Rev Anti Infect Ther
Aim: To better inform clinical practice, we summarized the findings from randomized controlled trials (RCTs) of antivirals for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Bassetti M, Giacobbe DR, Bruzzi P, et al. | Infect Dis Ther
Aim: To develop evidence-based guidance for the clinical management of adult patients with coronavirus disease 2019 (COVID-19) outside intensive care units.
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Feng Z, Yang J, Xu M, et al. | Clin Nutr ESPEN
Aim: To synthesize the available evidence from current existing RCTs and evaluate the impacts of DSs in people with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Angamo MT, Mohammed MA, Peterson GM | Infection
Aim: To synthesise the best available evidence on the effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Cammarota G, Esposito T, Azzolina D, et al. | Crit Care
Aim: To summarize the evidence on clinically relevant outcomes in COVID-19 patients supported by NIV outside the ICU. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Mittal N, Mittal R, Gupta MC, et al. | J Family Med Prim Care
Aim: To evaluate the therapeutic potential of CQ/HCQ given alone and in combination with azithromycin for treatment of confirmed COVID-19 infection caused by SARS-CoV-2, in comparison to standard management or other drugs. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/2/21
|
Ghasemian R, Shamshirian A, Heydari K, et al. | Int J Clin Pract
Aim: To review the evidence on the role of vitamin D in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/1/21
|
Hasan SS, Kow CS, Mustafa Z | Expert Rev Respir Med
Aim: To ascertain if methylprednisolone can be recommended for use in patients with COVID-19 to prevent deaths.
CANDIDATE THERAPEUTICS
|
|
|
7/30/21
|
Purnama A, Susaldi S, Mukhlida HZ, et al. | Open Access Macedonian Journal of Medical Sciences
Aim: To examine the description of mental health characteristics of health students who conducted studies during the Coronavirus disease (COVID)-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
7/29/21
|
de Candia P, Prattichizzo F, Garavelli S, et al. | iScience
Aim: To examine the effect of convalescent plasma in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/29/21
|
Nagraj S, Karia R, Hassanain S, et al. | Indian J Crit Care Med
Aim: To provide insight into the outcome of extracorporeal membrane oxygenation (ECMO) and invasive mechanical ventilation use in critically ill COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/29/21
|
Tobaiqy M, Qashqary M, Al-Dahery S, et al. | Infection Prevention in Practice
Aim: To report any evidence of therapeutics used for the management of patients with COVID-19 in clinical practice since emergence of the virus.
CANDIDATE THERAPEUTICS
|
|
|
7/28/21
|
Popp M, Stegemann M, Metzendorf MI, et al. | Cochrane Database Syst Rev
Aim: To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID?19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS?CoV?2 (postexposure prophylaxis).
CANDIDATE THERAPEUTICS
|
|
|
7/27/21
|
Konwar M, Maurya M, Bose D | Curr Drug Saf
Aim: To review the safety of Remdesivir in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/27/21
|
Mehraeen E, Najafi Z, Hayati B, et al. | Infect Disord Drug Targets
Aim: To describe the recent treatment strategies to treat COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/27/21
|
Kusumawardhani N, Dewi IP, Dharmadjati BB, et al. | J Saudi Heart Assoc
Aim: To systematically review and meta-analysis ECMO use in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/22/21
|
Noori M, Nejadghaderi SA, Arshi S, et al. | Rev Med Virol
Aim: To systematically review the most recent in vitro studies evaluating the effectiveness of BNT162b2 and mRNA-1273 induced neutralizing antibodies against SARS-CoV-2 variants of concern.
CANDIDATE THERAPEUTICS
|
|
|
7/19/21
|
Chivese T, Musa OAH, Hindy G, et al. | Travel Med Infect Dis
Aim: To synthesize findings from systematic reviews and meta-analyses on the efficacy and safety of chloroquine (CQ) and hydroxychloroquine (HCQ) with or without Azithromycin for treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/19/21
|
Alkofide H, Almohaizeie A, Almuhaini S, et al. | Int J Infect Dis
Aim: To systematically review the literature on the association between the combination of tocilizumab (TCZ) and systemic corticosteroid therapy (SCT) on outcomes of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/18/21
|
Elshafei MN, El-Bardissy A, Khalil A, et al. | Eur J Clin Invest
Aim: To assess colchicine's impact on mortality outcomes in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/15/21
|
Jiang F, Xu N, Zhou Y, et al. | Phytother Res
Aim: To review the efficacy and safety of treating COVID-19 with combined traditional Chinese medicine (TCM) and conventional western medicine (CWM). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/15/21
|
Aeen FB, Pakzad R, Rad MG, et al. | Sci Rep
Aim: To determine the effects of PP on respiratory parameters and outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/13/21
|
Viswanatha GL, Anjana Male CKVLSN, Shylaja H, et al. | Clin Exp Rheumatol
Aim: To evaluate the therapeutic benefits and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19) and associated health complications. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/13/21
|
Klopfenstein T, Gendrin V, Gerazime A, et al. | Infect Dis Ther
Aim: To conduct a subgroup meta-analysis between severe and non-severe COVID-19 treated by tocilizumab.
CANDIDATE THERAPEUTICS
|
|
|
7/12/21
|
Pavlov I, He H, McNicholas B, et al. | Respir Care
Aim: To synthesize the available evidence on the efficacy of APP.
CANDIDATE THERAPEUTICS
|
|
|
7/12/21
|
Gupta T, Thakkar P, Kalra B, et al. | Rev Med Virol
Aim: To evaluate the role of hydroxychloroquine (HCQ) in the treatment of COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
7/12/21
|
Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. | Diabetes Metab Syndr
Aim: To investigate the effect of ivermectin on mortality in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/12/21
|
Ebenezer O, Jordaan MA, Ogunsakin RE, et al. | Hippokratia
Aim: To identify active compounds with possibilities of combating COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
7/7/21
|
Malin JJ, Spinner CD, Janssens U, et al. | Infection
Aim: To provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Franchini M, Prefumo F, Grisolia G, et al. | Viruses
Aim: To systematically examine the current evidence on the clinical use of convalescent plasma during pregnancy. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Sosa JP, Ferreira Caceres MM, Ross Comptis J, et al. | Infect Chemother
Aim: To review the efficacy and safety of Interferon Beta in patients who have a confirmed COVID-19 diagnosis.
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Hernandez AV, Phan MT, Rocco J, et al. | J Clin Med
Aim: To review the efficacy and safety of hydroxychloroquine as treatment for hospitalized COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
de Matos BTL, Buchaim DV, Pomini KT, et al. | Life
Aim: To analyze the use of PBMT as a possible new approach as a complementary therapy in the treatment of patients affected by COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Romiti GF, Corica B, Lip GYH, et al. | J Clin Med
Aim: To investigate the epidemiology of AF in COVID-19 patients and its impact on all-cause mortality. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. | Infect Chemother
Aim: To assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
7/6/21
|
Rawat D, Roy A, Maitra S, et al. | Diabetes Metab Syndr
Aim: To investigate the role of supplementation of Vitamin D among COVID-19 patients on their disease outcomes.
CANDIDATE THERAPEUTICS
|
|
|
7/1/21
|
Abeldaño Zuñiga RA, González-Villoria RAM, Elizondo MV, et al. | Ther Adv Respir Dis
Aim: To determine the clinical effectiveness of convalescent plasma employed in the treatment of hospitalized patients with diagnosis of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/1/21
|
Gupta T, Kannan S, Kalra B, et al. | Transfus Med
Aim: To evaluate the safety and efficacy of convalescent plasma therapy in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/30/21
|
Chua EX, Zahir SMISM, Ng KT, et al. | J Clin Anesth
Aim: To investigate the effect of prone position on partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/30/21
|
Roman YM, Burela PA, Pasupuleti V, et al. | Clin Infect Dis
Aim: To assess benefits and harms of the use of ivermectin (IVM) in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
6/28/21
|
Lazarus G, Budiman RA, Rinaldi I, et al. | Cancer Immunol Immunother
Aim: To investigate the effects of ICI treatment on COVID-19 prognosis, including mortality, severity, and any other prognosis-related outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/28/21
|
Prakash A, Kaur S, Kaur C, et al. | Indian J Pharmacol
Aim: To analyze the effect of inhaled nitric oxide (iNO) in the treatment of severe COVID-19 and to compare it to standard of care (SOC), antiviral medications, and other medicines.
CANDIDATE THERAPEUTICS
|
|
|
6/28/21
|
Singh S, Khera D, Chugh A, et al. | BMJ Open
Aim: To evaluate remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/28/21
|
Chow R, Im J, Chiu N, et al. | PLoS One
Aim: To conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19 patients by statin usage. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/25/21
|
Richards H, Robins-Browne K, O'Brien T, et al. | Emerg Med J
Aim: To review the evidence relating to PP in the non-intubated patient with type 1 respiratory failure secondary to COVID-19 and other causes.
CANDIDATE THERAPEUTICS
|
|
|
6/25/21
|
Nawangsih EN, Kusmala YY, Rakhmat II, et al. | Int Immunopharmacol
Aim: To evaluate the effect of colchicine administration on mortality in patients with COVID-19 and factors affecting the association. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/25/21
|
Avogaro A, Bonora B, Fadini GP | Acta Diabetol
Aim: To determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality.
CANDIDATE THERAPEUTICS
|
|
|
6/25/21
|
Mendez-Brito A, El Bcheraoui C, Pozo-Martin F | J Infect
Aim: To evaluate which non-pharmaceutical interventions (NPIs) have been more and less effective in controlling the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
6/25/21
|
Pal R, Banerjee M, Bhadada SK, et al. | J Endocrinol Invest
Aim: To provide a precise summary and collate the hitherto available clinical evidence on the effect of vitamin D supplementation on clinical outcomes in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/24/21
|
Murchu EO, Spillane S, Byrne P, et al. | Ann Pharmacother
Aim: To conduct a systematic review on the effectiveness and safety of pharmacological and nonpharmacological interventions, in the ambulatory setting, aimed at preventing severe disease in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/24/21
|
Iyengar U, Jaiprakash B, Haitsuka H, et al. | Front Psychiatry
Aim: To provide a systematic review of mental health outcomes in pregnant and postpartum women during the COVID-19 pandemic
CANDIDATE THERAPEUTICS
|
|
|
6/23/21
|
Zhuang J, Dai X, Jin Z, et al. | Complement Ther Med
Aim: To evaluate the clinical efficacy of LQ on the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/23/21
|
Pinzon RT, Wijaya VO, Buana RB | J Infect Public Health
Aim: To synthesize the available evidence on the potential therapeutic effect of IL-6 inhibitor agents for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/21/21
|
Fancello V, Hatzopoulos S, Corazzi V, et al. | Int J Immunopathol Pharmacol
Aim: To describe the audio-vestibular disorders related to the newly SARS-CoV-2 infection, including the possible ototoxicity side-effects related to the use of drugs included in the SARS-CoV-2 treatment protocols.
CANDIDATE THERAPEUTICS
|
|
|
6/18/21
|
Hu Y, Song B | Research Square
Aim: To review the evidence on the relationship between use of antiplatelet agents and major outcomes of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
6/17/21
|
Zhang R, Gao Y, Xie D, et al. | Epidemiol Infect
Aim: To evaluate the cooperation between countries and institutions and the distribution of outcome measures in registered COVID-19 treatment SRs to provide a reference for researchers to register and carry out COVID-19 SRs.
CANDIDATE THERAPEUTICS
|
|
|
6/17/21
|
Singh RS, Singh A, Kaur H, et al. | Phytother Res
Aim: To summarize published works of literature on the effects of traditional Indian medicinal plants against acute respiratory infection (COVID-19, SARS, Influenza, and Respiratory syncytial virus infection) and registered clinical trials of traditional Indian herbal medicines in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/16/21
|
Di Castelnuovo A, Costanzo S, Cassone A, et al. | Pathog Glob Health
Aim: To evaluate the association between HCQ (with or without azithromycin (AZM)) and total mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
6/16/21
|
Saleki K, Yaribash S, Banazadeh M, et al. | Eur J Pharmacol
Aim: To assess the clinical efficacy of IFN-based treatments and combinational therapy with antivirals, corticosteroids, traditional medicine, and other treatments.
CANDIDATE THERAPEUTICS
|
|
|
6/15/21
|
Cheng B, Ma J, Yang Y, et al. | Front Pharmacol
Aim: To quantitatively reevaluate the efficacy of corticosteroids on COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/10/21
|
Nakhlband A, Fakhari A, Azizi H | J Med Virol
Aim: To investigate the efficiency of interferon-alpha against COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/10/21
|
Zein AFMZ, Sulistiyana CS, Raffaello WM, et al. | Postgrad Med J
Aim: To evaluate the effect of sofosbuvir/daclatasvir (SOF/DCV) on mortality, the need for intensive care unit (ICU) admission or invasive mechanical ventilation (IMV) and clinical recovery in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/9/21
|
Amani B, Khanijahani A, Amani B | Sci Rep
Aim: To examine the efficacy and safety of HCQ in addition to standard of care (SOC) in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/9/21
|
Matli K, Farah R, Maalouf M, et al. | Open Heart
Aim: To highlight the role of thrombosis in COVID-19 and provide new insights on the use of antithrombotic therapy in its management. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/8/21
|
Wu KS, Lin PC, Chen YS, et al. | Ann Med
Aim: To investigate the association between statins and COVID-19 outcomes and, if possible, identify the subgroup population that benefits most from statin use.
CANDIDATE THERAPEUTICS
|
|
|
6/8/21
|
Liang SB, Fang M, Liang CH, et al. | Complement Ther Med
Aim: To evaluate the therapeutic effects and safety of oral CPM for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/7/21
|
Elsayed HH, Hassaballa AS, Ahmed TA, et al. | PLoS One
Aim: To review the evidence on IMV for COVID-associated ARDS to study its outcome among different countries. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/3/21
|
Arfaras-Melainis A, Tzoumas A, Kokkinidis DG, et al. | J Cardiovasc Dev Dis
Aim: To assess the effect of hydroxychloroquine with or without the addition of azithromycin on the QTc of hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/3/21
|
Stroehlein JK, Wallqvist J, Iannizzi C, et al. | Cochrane Database Syst Rev
Aim: To assess whether vitamin D supplementation is effective and safe for the treatment of COVID?19 in comparison to an active comparator, placebo, or standard of care alone, and to maintain the currency of the evidence, using a living systematic review approach. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Nisar S, Farooq F, Rabia MN, et al. | Pakistan Journal of Medical & Health Sciences
Aim: To compare the high resolution computed tomography features in Covid and other viral pneumonia.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Seth T, Elavarasi A, Sahoo RK, et al. | Natl Med J India
Aim: To synthesize the available data on CP therapy for treatment of Covid-19 to study the efficacy and safety outcomes.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Malgie J, Schoones JW, Pijls BG | Clin Infect Dis
Aim: To review the evidence on whether IL-6 (receptor) antagonist therapy reduce mortality in COVID-19 patients compared to those not treated with IL-6 (receptor) antagonists.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Prasad M, Elavarasi A, Madan K, et al. | Natl Med J India
Aim: To review the evidence on the use of antivirals for Covid-19.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Shetty RM, Namachivayam AK | Indian J Crit Care Med
Aim: To review the evidence for the benefit of chloroquine/hydroxychloroquine in the treatment of patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Manabe T, Kambayashi D, Akatsu H, et al. | BMC Infect Dis
Aim: To review systematically on the application of favipiravir for patients with COVID-19 to identify empirical evidence of its efficacy.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Amani B, Khanijahani A, Amani B, et al. | J Pharm Pharm Sci
Aim: To provide the latest evidence on the efficacy and safety of lopinavir/ritonavir compared to other treatment options for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Radovanovic D, Coppola S, Franceschi E, et al. | J Crit Care
Aim: To analyse mortality and intubation rates in COVID-19 patients treated with NIV/CPAP.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Tasavon Gholamhoseini M, Yazdi-Feyzabadi V, Goudarzi R, et al. | J Pharm Pharm Sci
Aim: To assess the safety and efficacy of remdesivir in adult patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/1/21
|
Melesse DY, Chekol WB | Clin Nutr Open Sci
Aim: To review the evidence on the management of critically ill patients with COVID-19 in ICU in resource limiting settings.
CANDIDATE THERAPEUTICS
|
|
|
5/28/21
|
Arienti C, Lazzarini S, Pollini E, et al. | J Rehabil Med
Aim: To assess the effectiveness of rehabilitation interventions in adults with multiple organ dysfunction syndrome.
CANDIDATE THERAPEUTICS
|
|
|
5/28/21
|
Kaur U, Chakrabarti SS, Patel TK | Ther Adv Drug Saf
Aim: To provide a pooled estimate of the effect of RAAS blockers on COVID-19 outcomes.
CANDIDATE THERAPEUTICS
|
|
|
5/28/21
|
Sahilu T, Sheleme T, Melaku T | Interdiscip Perspect Infect Dis
Aim: To summarize the current evidence of the severity and mortality associated with steroid therapy for patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/28/21
|
Hassanipour S, Arab-Zozani M, Amani B, et al. | Sci Rep
Aim: To investigate the efficacy and safety of Favipiravir in treatment of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
5/24/21
|
Mangkuliguna G, Glendardi G, Susanto N, et al. | Tuberc Respir Dis
Aim: To investigate the efficacy and safety of Azithromycin in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/24/21
|
Patel TK, Patel PB, Barvaliya M, et al. | J Infect Public Health
Aim: To evaluate a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
5/24/21
|
Snow TAC, Saleem N, Ambler G, et al. | Intensive Care Med
Aim: To ascertain the benefit of IL-6 blockade with tocilizumab for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/21/21
|
Pulakurthi YS, Pederson JM, Saravu K, et al. | Medicine
Aim: To investigate the clinical outcomes associated with corticosteroid treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/21/21
|
Avni T, Leibovici L, Cohen I, et al. | QJM
Aim: To evaluate whether IL-6 inhibitor tocilizumab (TCZ) reduces mortality among hospitalized COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
5/20/21
|
Chen C, Hu F, Wei J, et al. | Leukemia
Aim: To determine safety and efficacy of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
5/20/21
|
Wei Q, Lin H, Wei R, et al. | Infect Dis Poverty
Aim: To review the evidence on tocilizumab treatment for COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
5/19/21
|
Barkas F, Ntekouan SF, Kosmidou M, et al. | Rheumatology
Aim: To assess the efficacy and safety of anakinra in adult hospitalized non-intubated patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/14/21
|
Munir MA, Tandiabang PA, Setyawati T, et al. | Transfus Clin Biol
Aim: To analyze the bioethical issues surrounding the potential use and study of convalescent plasma therapy in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/14/21
|
De Crescenzo F, Amato L, Cruciani F, et al. | Front Pharmacol
Aim: To assess the comparative efficacy and safety of pharmacological interventions for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/14/21
|
Heath L, Carey M, Lowney AC, et al. | Palliat Med
Aim: To determine the dose ranges of pharmacological interventions commonly used to manage symptoms in adult patients dying of COVID-19, establish how effectiveness of these interventions was measured, and whether the pharmacological interventions were effective. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/13/21
|
Nobari NN, Seirafianpour F, Dodangeh M, et al. | Exp Dermatol
Aim: To collect the mucocutaneous histopathologic data of COVID-19 patients for future investigations and interpretations.
CANDIDATE THERAPEUTICS
|
|
|
5/13/21
|
Okoli GN, Rabbani R, Copstein L, et al. | Infect Dis
Aim: To review the evidence on the treatment of COVID-19 with remdesivir.
CANDIDATE THERAPEUTICS
|
|
|
5/11/21
|
Wijaya I, Andhika R, Huang I, et al. | Clin Epidemiol Glob Health
Aim: To assess the efficacy of JAK inhibitors in terms of clinical outcome, including mortality, clinical improvement, and clinical deterioration among hospitalized COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/10/21
|
Taha M, Samavati L | RMD Open
Aim: To examine the prevalence of aPL and its clinical impact in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/10/21
|
Dong Y, Shamsuddin A, Campbell H, et al. | J Glob Health
Aim: To describe existing SARS-CoV-2 therapeutic approaches and present the results of their current COVID-19 clinical trials.
CANDIDATE THERAPEUTICS
|
|
|
5/10/21
|
Klassen SA, Senefeld JW, Johnson PW | Mayo Clin Proc
Aim: To determine the effect of COVID-19 convalescent plasma on mortality.
CANDIDATE THERAPEUTICS
|
|
|
5/10/21
|
Lazaridis D, Leung S, Kohler L, et al. | J Pharm Pract
Aim: To review the evidence on the impact of anticoagulation on COVID-19 patient outcomes.
CANDIDATE THERAPEUTICS
|
|
|
5/5/21
|
Shah R, Priyadarshini G, Parsana M | Indian J Otolaryngol Head Neck Surg
Aim: To give a brief review of available data on COVID-19 related to the timing, personal protections, operative steps modifications, and subsequent post tracheostomy care during this pandemic.
CANDIDATE THERAPEUTICS
|
|
|
5/3/21
|
Tleyjeh IM, Kashour Z, Riaz M, et al. | Clin Microbiol Infect
Aim: To perform a living systematic review of the literature about the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/1/21
|
Tharmarajah E, Buazon A, Patel V, et al. | J Infect
Aim: To assess the impact of IL-6 inhibition on mortality in the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/27/21
|
Bansal V, Mahapure KS, Mehra I, et al. | Front Med
Aim: To appraise the currently available data for the clinical usefulness of convalescent plasma for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/27/21
|
Ouyang L, Yu M, Zhu Y, et al. | Heliyon
Aim: To describe the respiratory supports and determine their association with clinical outcomes of COVID-19 patients in intensive care unit (ICU).
CANDIDATE THERAPEUTICS
|
|
|
4/26/21
|
Barreira DF, Lourenço RA, Calisto R, et al. | Front Med
Aim: To evaluate the potential of using CP or enriched antibodies from plasma (hyperimmune plasma) for the treatment of COVID-19 in comparison to standard treatment (ST) (treatments performed without CP), in clinical trials.
CANDIDATE THERAPEUTICS
|
|
|
4/22/21
|
Lu W, Zheng Y, Liu J, et al. | Aging
Aim: To evaluate the efficacy and safety of lopinavir/ritonavir antiviral treatment in patients with SARS, MERS, and COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/22/21
|
Chan KIP, Salonga AEM, Khu KJO | Surg Neurol Int
Aim: To review the evidence on decompressive hemicraniectomy for acute ischemic stroke and share a case presentation.
CANDIDATE THERAPEUTICS
|
|
|
4/22/21
|
Qiu R, Li J, Xiao Y, et al. | Medicine
Aim: To evaluate the efficiency and safety of the COVID-19 medicine.
CANDIDATE THERAPEUTICS
|
|
|
4/21/21
|
Moonla C, Sosothikul D, Chiasakul T, et al. | Clin Appl Thromb Hermost
Aim: To estimate pooled odds ratios (ORs) of in-hospital mortality and major bleeding comparing among intermediate-to-therapeutic dose AC, prophylactic dose AC, and no AC.
CANDIDATE THERAPEUTICS
|
|
|
4/21/21
|
Chaudhuri D, Sasaki K, Aram K, et al. | Intensive Care Med
Aim: To summarize all RCTs examining the use of corticosteroids in ARDS.
CANDIDATE THERAPEUTICS
|
|
|
4/19/21
|
Morris AM, Bean S, Bell CM, et al. | Ontario COVID-19 Science Advisory Table
Aim: To review the evidence on strategies to manage tocilizumab supply during the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
4/15/21
|
Parisi R, Costanzo S, Di Castelnuovo A, et al. | Semin Thromb Hemost
Aim: To assess the association of anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
4/13/21
|
Ibekwe T, Ibekwe P, Orimadegun EA | Ann Med Surg
Aim: To review the evidence on the effectiveness of Remdesivir in the management of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/12/21
|
Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M, et al. | Travel Med Infect Dis
Aim: To describe the assessment and treatment of asymptomatic infection in patients with a confirmed diagnosis of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/12/21
|
Badkhsh M, Dastras M, Sarchahi Z, et al. | Rev Environ Health
Aim: To evaluate the effect of CAM interventions on COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
4/12/21
|
Rakhmat II, Kusmala YY, Handayani DR, et al. | Diabetes Metab Syndr
Aim: To synthesize evidence on dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in COVID-19 patients and factors affecting it. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/12/21
|
Vafea MT, Zhang R, Kalligeros M, et al. | Expert Rev Med Devices
Aim: To evaluate existing information about mortality rates and effectiveness of antiviral, immune-modulating, and anticoagulation treatments in COVID-19 patients who received mechanical ventilation.
CANDIDATE THERAPEUTICS
|
|
|
4/9/21
|
Morales-Cane I, del Rocio Valverde-Leon M, Gonzalez-Gancedo J, et al. | Eur Rev Med Pharmacol Sci
Aim: To synthesize and analyze the scientific publications related to ventilatory therapies used in patients with COVID-19 in Intensive Care Units (ICUs), the parameters of invasive mechanical ventilation prescribed for these patients, and the clinical characteristics of patients admitted to the ICU. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/8/21
|
Peng HT, Rhind SG, Beckett A, et al. | JMIR Public Health Surveill
Aim: To characterize the latest advances and evidence in the use of CP for COVID-19 through a systematic review and quantitative analysis, identify knowledge gaps in this setting, and offer recommendations and directives for future research.
CANDIDATE THERAPEUTICS
|
|
|
4/8/21
|
Rezaei S, Fatemi B, Majd ZK, et al. | Expert Rev Clin Immunol
Aim: To combine the results of clinical studies of different designs to investigate the efficacy and safety of tocilizumab in severely-to-critically ill COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/6/21
|
Barzkar F, Ranjbar M, Sioofy-Khojine AB, et al. | Med J Islam Repub Iran
Aim: To synthesize current evidence systematically for in vitro, animal, and human studies on the efficacy and safety of chloroquine in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/6/21
|
Eze P, Mezue KN, Nduka CU, et al. | Am J Cardiovasc Dis
Aim: To evaluate the efficacy and safety of CQ and HCQ in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/6/21
|
Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM, et al. | Front Endocrinol
Aim: To summarize the available evidence on the potential mechanism of action and the efficacy of metformin in COVID-19 patients with DM.
CANDIDATE THERAPEUTICS
|
|
|
4/5/21
|
Lin W, Hung S, Lai C, et al. | Int Immunopharmacol
Aim: To investigate the clinical efficacy and safety of tocilizumab for treating patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/5/21
|
Wang Z, Wang Y, Yang Z, et al. | Int J Infect Dis
Aim: To appraise the quality and availability of guidelines stated and whether non-invasive ventilation in the early stage of the pandemic is of importance. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/4/21
|
Kow CS, Hasan SS | J Thromb Thrombolysis
Aim: To explore the overall effect of the use of antiplatelets in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/2/21
|
Abdelrahman Z, Liu Q, Jiang S, et al. | Front Pharmacol
Aim: To estimate the impact of current treatments on the efficacy and safety of COVID-19 by a meta-analysis. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
4/1/21
|
Belashew GT, Hanumanthaiah P, Namo FM, et al. | J Pharmaceut Res Int
Aim: To review completed clinical trials in humans due to coronavirus disease 2019 to recommend ways to overcome the pandemic.
CANDIDATE THERAPEUTICS
|
|
|
4/1/21
|
Carvalho APA, Conte-Junior CA | Glob Chall
Aim: To critically analyze nanomaterials? role as both a primary strategy (when the nanomaterials interact directly with the virus) and a secondary approach (when the nanomaterials improve the efficacy of another antiviral agent) against coronaviruses.
CANDIDATE THERAPEUTICS
|
|
|
3/31/21
|
Choudhuri AH, Duggal S, Ahuja B, et al. | Indian J Med Microbiol
Aim: To address the efficacy and safety of HCQ in SARS CoV2 by overcoming the limitations of earlier meta-analysis.
CANDIDATE THERAPEUTICS
|
|
|
3/30/21
|
Bassatne A, Basbous M, Chakhtoura M, et al. | Metabolism
Aim: To assess the impact of vitamin D status and supplementation on COVID-19 related mortality and health outcomes. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/29/21
|
Abeldano RA, Coca SM, Abeldano GF, et al. | Ther Adv Respir Dis
Aim: To assess the clinical effectiveness of drugs used in hospitalized patients with COVID-19 infection. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/29/21
|
Papotsi E, Giannakoulis VG, Xourgia E, et al. | Crit Care
Aim: To investigate the effect (if any) of timing of intubation on clinical outcomes of critically ill patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/29/21
|
Diaz-Arocutipa C, Branez-Condorena A, Hernande AV | Pharmacoepidemiol Drug Saf
Aim: To assess the prevalence and risk of QTc prolongation and arrhythmic events in COVID-19 patients treated with these drugs.
CANDIDATE THERAPEUTICS
|
|
|
3/29/21
|
Kow CS, Merchant HA, Mustafa ZU, et al. | Pharmacol Rep
Aim: To investigate the overall effect of ivermectin on the risk of mortality in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/26/21
|
Nugroho CW, Suryantror SD, Yuliasih Y, et al. | F1000Res
Aim: To research the risks and benefits of tocilizumab and investigate outcomes from different baseline criteria for administration of tocilizumab as a treatment for severe and critically ill COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
3/25/21
|
Lai C, Chen C, Wang C, et al. | J Antimicrob Chemother
Aim: To provide updated information regarding the clinical efficacy of remdesivir in treating coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/24/21
|
Raju R, V P, Biatris PS, et al. | Futur J Pharm Sci
Aim: To analyze various trials registered across the globe providing an overall picture of the use of corticosteroids in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/23/21
|
Prasad M, Seth T, Elavarasi A | Indian J Hematol Blood Transfus
Aim: To study the efficacy and safety of convalescent plasma in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/23/21
|
Chenchula S, Ray A, Sadasivam B | Drug Res
Aim: To study all the available scientific evidence on famotidine research outcomes systematically to introspect its clinical efficacy and probable mechanisms and clinical efficacy against SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
3/19/21
|
Welte T, Ambrose LJ, Sibbring GC, et al. | Eur Respir Rev
Aim: To identify clinical trials of pharmacological interventions for COVID-19 and evaluate for effectiveness. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/19/21
|
Ghosn L, Chaimani A, Evrenoglou T, et al. | Cochrane Database Syst Rev
Aim: To assess the effect of IL?6 blocking agents compared to standard care alone or with placebo on efficacy and safety outcomes in COVID?19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/18/21
|
Shi S, Wang F, Li J, et al. | IUBMB Life
Aim: To test the efficacy of CHM on digestive symptoms and liver function (primary outcomes), the aggravation of COVID-19 and the time to viral assay conversion (secondary outcomes), among patients with COVID-19, compared with standard pharmacotherapy.
CANDIDATE THERAPEUTICS
|
|
|
3/16/21
|
Hariyanto TI, Halim DA, Jodhinata C, et al. | Clin Exp Pharmacol Physiol
Aim: To analyze the efficacy of colchicine administration and outcomes of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/16/21
|
Bokharee N, Khan YH, Khokhar A, et al. | Expert Rev Anti Infect Ther
Aim: To systematically analyze the published and ongoing studies evaluating the pharmacological interventions for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/15/21
|
Juul S, Nielsen N, Feinberg J, et al. | PLoS Med
Aim: To compare the effects of all treatment interventions for participants in all age groups with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/12/21
|
Sharma D, Sharma N, Sharma P, et al. | J Educ Health Promot
Aim: To discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
3/11/21
|
Cruciani F, Amato L, De Crescenzo F, et al. | Recenti Prog Med
Aim: To synthesize and evaluate the quality of evidence of efficacy and safety for the treatment.
CANDIDATE THERAPEUTICS
|
|
|
3/10/21
|
Meena J, Jain S, Kumar j, et al. | J Infect Chemother
Aim: To systematically synthesize the evidence over the efficacy and safety of HCQ or CQ alone as compared to placebo or no active intervention in adults with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/8/21
|
Ho TC, Wang YH, Chen YL | Pathogens
Aim: To synthesize articles regarding the cure of COVID-19 by CQ or HCQ and depict the efficacy of these drugs for COVID-19 treatment.
CANDIDATE THERAPEUTICS
|
|
|
3/8/21
|
Cordeiro LP, Linhares EONN, Nogueira FGO, et al. | Pharmacol Rep
Aim: To systematically review the studies that described the use of GC in patients with COVID-19 and to provide a safer analysis of the effectiveness and recommendations for GC use.
CANDIDATE THERAPEUTICS
|
|
|
3/5/21
|
Zhan Y, Shang J, Gu Y, et al. | J Med Virol
Aim: To evaluate the efficacy of corticosteroids on COVID-19 patients with different levels of disease severity.
CANDIDATE THERAPEUTICS
|
|
|
3/1/21
|
Diallo A, Carlos-Bolumbu M, Traore M, et al. | J Public Health Res
Aim: To compare and rank the efficacy and safety of treatments tested in patients with SARSCoV- 2 virus. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
3/1/21
|
Janiaud P, Axfors C, Schmitt AM, et al. | JAMA
Aim: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs).
CANDIDATE THERAPEUTICS
|
|
|
3/1/21
|
Goodwin VA, Allan L, Bethel A, et al. | Physiotherapy
Aim: To establish the evidence for rehabilitation interventions tested in populations of patients admitted to ICU and critical care with severe respiratory illness, and consider whether the evidence is generalizable to patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
3/1/21
|
Sabe M, Dorsaz O, Hugguelet P, et al. | Gen Hosp Psychiatry
Aim: To review clinical evidence regarding the potential toxicity/side effects of psychiatric medications in the context of SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
2/26/21
|
Liang S, Zhang Y, Shen C, et al. | Front Pharmacol
Aim: To further probe the role of CHM used with or without conventional western therapy on the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/26/21
|
Aibakr AA, Ingle NA, Assery MK, et al. | Ann Med Health Sci Res
Aim: To identify the role of corticosteroids on coronavirus infection and to compare the mortality and morbidity rate of steroid intervened corona virus infected patients.
CANDIDATE THERAPEUTICS
|
|
|
2/26/21
|
Sun C, Chen Y, Hu L, et al. | Dig Dis Sci
Aim: To assess effects of famotidine on improving the outcome of those suffered COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/23/21
|
Avianai JK, Halim D, Soeroto AY, et al. | Rev Med Virol
Aim: To evaluate CPT potentials in COVID-19 treatment, by performing systematic review and meta-analysis of studies in COVID-19 and other similar viral respiratory diseases, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and Influenza. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/22/21
|
Conrado PCV, Sakita KM, Arita GS, et al. | Photodiagnosis Photodyn Ther
Aim: To assess whether photodynamic therapy and its mechanisms of action could be effective in inactivating SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
2/22/21
|
Hawkins RB, Mehaffey JH, Charles EJ, et al. | Transplantation
Aim: To review the evidence on lung transplantation for severe post-coronavirus disease 2019 respiratory failure, including patient selection, perioperative management, and expected outcomes.
CANDIDATE THERAPEUTICS
|
|
|
2/22/21
|
Karimian M, Mansouri F, Borji M, et al. | Arch Clin Infect Dis
Aim: To systematically review studies on the prevention, diagnosis, and treatment of coronavirus in infants and children.
CANDIDATE THERAPEUTICS
|
|
|
2/22/21
|
Roshanshad A, Kamalipour A, Ashraf MA, et al. | Iran J Microbiol
Aim: To investigate the latest clinical evidence on the efficacy and safety of treatment with Remdesivir in hospitalized patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/22/21
|
Rahimzadeh M, Naderi N | J Med Virol
Aim: To shed light on COVID-19 mediated immune malfunction and highlight possible clues for effective treatments of this disease.
CANDIDATE THERAPEUTICS
|
|
|
2/17/21
|
de Souza DB, Frondana FV, Silva FD | Res Biomed Engineering
Aim: To establish reference parameters of ventilatory therapy used in the various levels of severity of adult patients affected by COVID-19, to assist health professionals and hospital managers who will purchase this equipment.
CANDIDATE THERAPEUTICS
|
|
|
2/17/21
|
Bonora BM, Avogaro A, Fadini GP | J Endocrinol Invest
Aim: To summarize the current state of the art on DPP4i treatment and COVID-19-related outcomes in patients with diabetes mellitus.
CANDIDATE THERAPEUTICS
|
|
|
2/17/21
|
Nakhlband A, Fakhari A, Azizi H | Naunyn Schmiedebergs Arch Pharmacol
Aim: To assess outcomes of IFN-beta treatment in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/17/21
|
Bansal V, Mahapure KS, Bhurwal A, et al. | Front Med
Aim: To provide a detailed overview of existing literature on Remdesivir in COVID-19 to evaluate the benefits and adverse events.
CANDIDATE THERAPEUTICS
|
|
|
2/17/21
|
Kheyami ZA, Alharthi SS, Alanazi NS, et al. | Ann Med Health Sci Res
Aim: To determine the safety of systemic steroids and mortality rate in severe COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Umakanthan S, Chattu VK, Ranade AV, et al. | AIMS Public Health
Aim: To give a detailed insight into the recent trends of diagnosis and therapeutic options for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Sharifian-Dorche M, Sahraian MA, Fadda G, et al. | Mult Scler Relat Disord
Aim: To review the existing literature investigating the impact of disease-modifying therapies(DMT) on COVID-19 risks in this group of patients.
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Ebina-Shibuya R, Namoong H, Horita N, et al. | J Thorac Dis
Aim: To evaluate HCQ/CQ treatment for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Khan FA, Stewart I, Fabbri L, et al. | Thorax
Aim: To systematically review and assess the effectiveness of specific interleukin-1 and -6 inhibitors for the treatment of coronavirus-related infections. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Darbandi A, Asadi A, Ghanavati R, et al. | Int J Infect Dis
Aim: To evaluate the effects of probiotic on patient’s respiratory tract infection (RTI), a systematic review was conducted on randomized controlled trials (RCTs).
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Bignardi PR, Vengrus CS, Aquino BM, et al. | Pathog Glob Health
Aim: To assess the association of hydroxychloroquine use with the virological cure, clinical recovery, mortality, and development of adverse effects in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/16/21
|
Sarfraz A, Sarfraz Z, Razzack AA, et al. | Clin Appl Thromb Hermost
Aim: To determine the risk of developing VTE after corticosteroid administration during COVID-19 treatment.
CANDIDATE THERAPEUTICS
|
|
|
2/12/21
|
Singh B, Ryan H, Kredo T, et al. | Cochrane Database Syst Rev
Aim: To evaluate the effects of chloroquine or hydroxychloroquine for treatment people with COVID-19 and for preventing infection in people at risk of exposure or exposed to SARS-CoV-2. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/9/21
|
Chedid M, Waked R, Haddad E, et al. | J Infect Public Health
Aim: To report available information in the literature regarding frequency, indications, types of antibiotic usage, duration, and their efficacy in Covid-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/8/21
|
Bhatta M, Nandi S, Dutta S, et al. | Hum Vaccin Immunother
Aim: To analyze the availability, development and status of new COVID-19 vaccine candidates as well as the status of vaccines for other diseases that might be effective against SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
2/8/21
|
Vegivinti CTR, Pederson JM, Saravu K, et al. | J Clin Apher
Aim: To examine clinical outcomes associated with convalescent plasma therapy in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/8/21
|
Pal R, Banerjee M, Yadav U, et al. | Postgrad Med J
Aim: To provide an updated summary and collate the effect of statin use on clinical outcomes in COVID-19 using unadjusted and adjusted risk estimates.
CANDIDATE THERAPEUTICS
|
|
|
2/5/21
|
Pasin L, Cavalli G, Navalesi P, et al. | Eur J Intern Med
Aim: To investigate the effect of anakinra in COVID-19 on survival and need for mechanical ventilation.
CANDIDATE THERAPEUTICS
|
|
|
2/4/21
|
Rezagholizadeh A, Khiali S, Sarbakhsh P, et al. | Eur J Pharmcol
Aim: To evaluate the efficacy and safety of remdesivir administration in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
2/3/21
|
Li J, Liao X, Zhou Y, et al. | Shock
Aim: To review the evidence on the response to glucocorticioids treatment in COVID-19 and SARS patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/1/21
|
AlJohani AMA, Tharwat TJA, Mahrous KW, et al. | World Fam Med J
Aim: To outline and identify a wide range of diagnostic and therapeutic options for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
2/1/21
|
Agostini F, Mangone M, Ruiu P, et al. | J Rehabil Med
Aim: To identify the best evidence to define rehabilitative approaches to acute and post-acute phases of coronavirus 2019 (COVID-19) disease.
CANDIDATE THERAPEUTICS
|
|
|
2/1/21
|
Al-abdouh A, Bizanti A, Barbarawi M, et al. | Contemp Clin Trials
Aim: To evaluate the effect of remdesivir in the treatment of moderate and severe COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
2/1/21
|
Han YJ, Lee KW, Yoon S, et al. | Theranostics
Aim: To highlight therapeutic agents that might be effective in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/29/21
|
Kinobe RT, Owens L | Fundam Clin Pharmacol
Aim: To present an integrative, critical appraisal of the qualitative and quantitative antiviral properties of ivermectin for putative applications in agriculture and medicine with examination of SARS?CoV?2.
CANDIDATE THERAPEUTICS
|
|
|
1/29/21
|
Arias FA, Chavez PT, Panato AM, et al. | J of Pharmaceutical Res
Aim: To conduct a systematic review of the possible antivirals studied that could be useful in this public health catastrophe.
CANDIDATE THERAPEUTICS
|
|
|
1/29/21
|
Rodriguez-Guerra M, Jadhav P, Vittorio TJ | Drugs Context
Aim: To assess the efficacy and safety of these available therapies in light of current evidence.
CANDIDATE THERAPEUTICS
|
|
|
1/29/21
|
Cao C, Wang J, Li Y, et al. | Int J Clin Pract
Aim: To evaluate the relationship between OM-85 consumption and recurrent respiratory tract infections.
CANDIDATE THERAPEUTICS
|
|
|
1/27/21
|
Manzo-Toledo A, Torres-Rosas R, Mendieta-Zeron H, et al. | Med J Indones
Aim: To systematically evaluate the available evidence on the effectiveness of HCQ in the treatment of COVID-19 disease.
CANDIDATE THERAPEUTICS
|
|
|
1/27/21
|
Vegivinti CTR, Pederson JM, Saravu K, et al. | Ann Med Surg
Aim: To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/26/21
|
Kumar S, Sarma P, Kaur H, et al. | Tissue Cell
Aim: To review the evidence on the utility of different cell culture systems as potential in-vitro models for repurposing and drugs development, vaccine development, isolation and pathogenesis of SARS-COV-2.
CANDIDATE THERAPEUTICS
|
|
|
1/22/21
|
Rakedzon S, Neuberger A, Domb AJ, et al. | J Travel Med
Aim: To review data on the potential of repurposing antiparasitic drugs against viruses in general, with an emphasis on coronaviruses.
CANDIDATE THERAPEUTICS
|
|
|
1/22/21
|
Onorato D, Pucci M, Carpene G, et al. | Semin Thromb Hemost
Aim: To provide an updated overview on the interplay between statins and COVID-19, with particular focus on their potentially protective role against progression toward severe or critical illness and death.
CANDIDATE THERAPEUTICS
|
|
|
1/18/21
|
Kow CS, Hasan SS | J Asthma
Aim: To review the evidence on the overall effect of the chronic use of inhaled corticosteroids on the clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
1/18/21
|
Smit M, Marinosci A, Agoritsas T, et al. | Clin Microbiol Infect
Aim: To review the evidence on a pre- and post-exposure prophylactic (PrEP and PEP) candidate for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/7/21
|
Lukito AA, Pranata R, Henrina J, et al. | Diabetes Metab Syndr
Aim: To review the evidence on metformin consumption and mortality in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/6/21
|
Andrade BS, Rangel FS, Santos NO, et al. | Front Pharmacol
Aim: To review the evidence on drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols.
CANDIDATE THERAPEUTICS
|
|
|
1/6/21
|
Lewis K, Chaudhuri D, Alshamsi F, et al. | PLoS One
Aim: To determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/6/21
|
Zaffanello M, Piacentini G, Nosetti L, et al. | Transfus Apher Sci
Aim: To review the literature and ongoing clinical trials on convalescent plasma therapy in pediatric patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/5/21
|
Hariyanto TI, Hardyson W, Kurniawan A | Drug Res
Aim: To give clear evidence regarding the potential benefit and safety of tocilizumab in improving the outcome of COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
1/4/21
|
Aerobic exercises recommendations and specifications for patients with COVID-19: a systematic review
 Alawna M, Amro M, Mohamed AA | Eur Rev Med Pharmacol Sci
Aim: To systematically analyze the effects of aerobic exercise on immunological biomarkers to provide safe aerobic exercise recommendations and specifications for patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/4/21
|
Rada G, Corbalan J, Rojas P, et al. | Medwave
Aim: To provide a timely, rigorous and continuously updated summary of the available evidence on the role of cell-based therapies in the treatment of patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/4/21
|
Kim MS, An MH, Kim WJ, et al. | PLoS One
Aim: To evaluate the comparative efficacy and safety of pharmacological interventions used in treating COVID-19 and form a basis for an evidence-based guideline of COVID-19 management by evaluating the level of evidence behind each treatment regimen in different clinical settings. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/4/21
|
Han Q, Guo M, Zheng Z, et al. | Front Pharmacol
Aim: To assess the safety and efficacy of anti-IL-6 signaling (anti-IL6/IL-6R/JAK) agents on COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
1/4/21
|
Choupoo NS, Das SK, Haldar R, et al. | Indian J Crit Care Med
Aim: To test the efficacy of different therapeutic options currently available for treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
1/3/21
|
de Souza DB, de Oliveira Andrade A, Milagre ST, et al. | Research on Biomedical Engineering
Aim: To carry out a systematic review of the advantages and disadvantages of possible solutions in oxygenation support.
CANDIDATE THERAPEUTICS
|
|
|
12/30/20
|
McEwan T, Robinson PC | Semin Arthritis Rheum
Aim: To systematically examine infectious adverse events associated with colchicine usage and the clinical use of colchicine for infectious diseases.
CANDIDATE THERAPEUTICS
|
|
|
12/30/20
|
de Oliveira TF, de Oliveira Rocha CA, dos Santos AGG, et al. | Braz J Cardiovasc Surg
Aim: To systematically review the literature on the use of extracorporeal membrane oxygenation (ECMO) in patients with coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
12/30/20
|
Verdejo C, Vergara-Merino L, Meza N, et al. | Medwave
Aim: To provide a timely, rigorous, and continuously updated summary of the evidence available on the role of macrolides for treating patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/23/20
|
Prendki V, Tau N, Avni T, et al. | BMC Geriatr
Aim: To examine the participation of elderly patients in therapeutic or prophylactic trials on COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/22/20
|
Ghazy RM, Almaghraby A, Shaaban R, et al. | Sci Rep
Aim: To review the evidence on the effectiveness and safety of either CQ or HCQ alone or in combination with AZM in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/22/20
|
Piombino P, Troise S, Vargas M, et al. | Eur Rev Med Pharmacol Sci
Aim: To analyze the scientific literature identifying the indications for tracheostomy and safety precautions to reduce contamination.
CANDIDATE THERAPEUTICS
|
|
|
12/22/20
|
Oikonomidi T, Boutron I, Pierre O, et al. | BMC Med
Aim: To describe the proportion of evidence on the effect of interventions for COVID-19 from preprints and journal articles and map changes in evidence between and within different sources reporting on the same study.
CANDIDATE THERAPEUTICS
|
|
|
12/22/20
|
Wang Y, Huo P, Dai R, et al. | Int Immunopharmacol
Aim: To evaluate the existing evidence and experience related to CP immunotherapy for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/22/20
|
Lee MMY, Docherty KF, Sattar N, et al. | Eur Heart J Cardiovasc Pharmacother
Aim: To provide summary odds ratio (OR) estimates for associations between treatment with (vs. without) renin-angiotensin system (RAS) blockers and risk of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and coronavirus disease 2019 (CoViD-19) severity (including case-fatality) in patients with hypertension, and in all patients (irrespective of hypertension).
CANDIDATE THERAPEUTICS
|
|
|
12/18/20
|
Wenjing L, Yuanzheng F, Li JY, et al. | Aging
Aim: To review the evidence on the safety and efficacy of CP transfusion in SARS-CoV-2-infected patients.
CANDIDATE THERAPEUTICS
|
|
|
12/17/20
|
van Paassen J, Vos JS, Hoekstra EM, et al. | Crit Care
Aim: To evaluate the effect of corticosteroids on mortality, viral clearance and secondary outcomes in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/16/20
|
Khalili M, Chegeni M, Javadi S, et al. | Ther Adv Respir Dis
Aim: To provide a succinct summary of the findings of systematic reviews on different pharmacological and non-pharmacological therapeutic interventions for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/14/20
|
Nobari NN, Seirafianpour F, Mashayekhi F, et al. | Dermatol Ther
Aim: To review the evidence on treatment-related mucocutaneous drug reactions of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/14/20
|
Piscoya A, Ng-Sueng LF, del Riego AP, et al. | PLoS One
Aim: To evaluate the efficacy and safety of remesdivir for the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
12/14/20
|
Kaushal K, Sarma P, Rana SV, et al. | J Biomol Struct Dyn
Aim: To evaluate the role of AI in drug repurposing, novel drug discovery, vaccine and antibody development for the therapeutics of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
12/11/20
|
Celotto S, Veronese N, Barbagallo M, et al. | Int J Infect Dis
Aim: To evaluate the strength and credibility of the evidence derived from systematic reviews with meta-analyses (MAs) of observational and intervention studies regarding HCQ/CQ, their importance to health outcomes and their side effects.
CANDIDATE THERAPEUTICS
|
|
|
12/2/20
|
Das RR, Behera B, Mishra B, et al. | Indian J Med Microbiol
Aim: To review the effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes.
CANDIDATE THERAPEUTICS
|
|
|
11/28/20
|
Pasin L, Navalesi P, Zangrillo A, et al. | J Cardiothorac Vasc Anesth
Aim: To evaluate the effect of corticosteroid therapy in patients with COVID-19 at different severity levels.
CANDIDATE THERAPEUTICS
|
|
|
11/27/20
|
Dar-Odeh N, Elsayed S, Babkair H, et al. | J Dent Sci
Aim: To highlight COVID-19 pharmacotherapeutic agents that are relevant to dental practice in terms of their clinical indications in COVID-19 and dental practice, as well as their adverse effects as they impact the dental patient.
CANDIDATE THERAPEUTICS
|
|
|
11/24/20
|
Zhang G, Wu Y, Xu R, et al. | J Med Virol
Aim: To explore whether the use of RAAS inhibitors was associated with severe disease and mortality in COVID?19 patients.
CANDIDATE THERAPEUTICS
|
|
|
11/24/20
|
Perveen RA, Nasir M, Talha KA, et al. | Med J Malaysia
Aim: To evaluate the effectiveness of antiviral therapies in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/20/20
|
Takla M, Jeevaratnam K | Saudi Pharm J
Aim: To systematically identify and collate 24 studies describing the use of CQ and HCQ in human clinical trials and to provide a detailed synthesis of evidence of its efficacy and safety.
CANDIDATE THERAPEUTICS
|
|
|
11/20/20
|
Nunes JPL | Porto Biomed J
Aim: To perform a systematic review on mortality associated to the use of ACEi in patients with COVID-19 disease.
CANDIDATE THERAPEUTICS
|
|
|
11/20/20
|
Faraone I, Labanca F, Ponticelli M, et al. | Molecules
Aim: To analyze preclinical and clinical studies on HCQ potential use in viral infection and chronic diseases.
CANDIDATE THERAPEUTICS
|
|
|
11/20/20
|
Zreiq R, Haouas N, Khemakhem AM, et al. | J of Pharmaceutical Res
Aim: To review the "state-of-the-art" of treatment modalities and propose a practical therapeutic algorithm for the COVID-19 management.
CANDIDATE THERAPEUTICS
|
|
|
11/20/20
|
Zhao M, Lu J, Tang Y, et al. | Eur J Clin Pharmacol
Aim: To explore the effectiveness and safety of tocilizumab recently used for treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/19/20
|
Case Fatality Rates for COVID-19 Patients Requiring Invasive Mechanical Ventilation: A Meta-analysis
Lim ZJ, Subramaniam A, Reddy MP, et al. | Am J Respir Crit Care Med
Aim: To examine the case fatality rate of patients with COVID-19 receiving invasive medical ventilation.
CANDIDATE THERAPEUTICS
|
|
|
11/19/20
|
Zhang JJY, Lee KS, Ang LW, et al. | Clin Infect Dis
Aim: To (1) investigate the predictive value of laboratory investigations for severe disease and adverse outcomes and (2) evaluate the efficacy of antivirals and corticosteroids for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/18/20
|
Kaye A, Siegel R | PeerJ
Aim: To investigate and synthesize existing evidence for the efficacy of TCZ in reducing COVID-19 mortality. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/16/20
|
Joseph B, Dibas M, Evanson KW, et al. | Expert Rev Anti Infect Ther
Aim: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
11/13/20
|
Li H, Hu Y, Tang H, et al. | Am J Chin Med
Aim: To systematically review evidence on the efficacy and safety of glycyrrhizin preparations for SARS and MERS for application to COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
11/11/20
|
Oscanoa TJ, Vidal X, Kanters JK, et al. | Int J Antimicrob Agents
Aim: To conduct a meta-analysis of the frequency of LQT in patients with SARS-CoV-2 infection treated with HCQ.
CANDIDATE THERAPEUTICS
|
|
|
11/11/20
|
Tleyjeh I, Kashour Z, Al Dosary O, et al. | Mayo Clin Proc Innov Qual Outcomes
Aim: To systematically review the literature and estimate the risk of cardiac toxicity in patients receiving CQ or HCQ for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
11/9/20
|
Ren L, Xu W, Overton JL, et al. | Front Pharmacol
Aim: To examine the safety profiles of these medications, we systematically evaluated the adverse events (AEs) of these medications from published randomized controlled trials (RCTs). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/28/20
|
Mora-Ramirez M, Melgoza-Hernandez P, Toledo-Ramirez SE, et al. | Curr Med Chem
Aim: To review the main adverse effects regarding the most prescribed drugs and, specifically, the efficacy and potential risk of each pharmacological therapy, during hospital care for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/28/20
|
Cano EJ, Fuentes XF, Campioli CC, et al. | Chest
Aim: To review the evidence on the impact of corticosteroids in mortality, ICU admission, mechanical ventilation, and viral shedding in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
10/27/20
|
Budhathoki P, Shrestha DB, Rawal E, et al. | SN Compr Clin Med
Aim: To assess the rationality on the use of corticosteroids in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/26/20
|
Weatherald J, Solverson K, Zuege DJ, et al. | J Crit Care
Aim: To quickly identify and synthesize studies examining the effect of awake prone positioning on patients with hypoxemic respiratory failure (including those with ARDS and/or COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/26/20
|
Mch SA, Baishya M, Singh A, et al. | Trends Anaesthesia Crit Care
Aim: To conduct a systematic review of the available literature to highlight the effect of awake proning on the need for intubation, improvement in oxygenation and mortality rates in COVID-19 patients with ARDS.
CANDIDATE THERAPEUTICS
|
|
|
10/26/20
|
Hu C, Liang M, Gong F, et al. | Evid Based Complement Alternat Med
Aim: To investigate and compare the therapeutic effect of Lianhua Qingwen with conventional drugs on pneumonia symptoms.
CANDIDATE THERAPEUTICS
|
|
|
10/26/20
|
Wang Y, Chen B, Li Y, et al. | J Med Virol
Aim: To investigate the effects of ACEI/ARB on COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
10/25/20
|
Kotak S, Khatri M, Malik M, et al. | Cureus
Aim: To assess the safety and efficacy of tocilizumab as compared to the standard regimen in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/22/20
|
Wijaya I, Andhika R, Huang I | Clin Appl Thromb Hemost
Aim: To explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/22/20
|
Kurdi A, Abutheraa N, Akil L, et al. | Pharmacol Res Perspect
Aim: To provide a comprehensive/updated evaluation of the effect of ACEIs/ARBs on COVID?19?related clinical outcomes, including exploration of interclass differences between ACEIs and ARBs.
CANDIDATE THERAPEUTICS
|
|
|
10/22/20
|
Qadri SK, Ng P, Toh TSW, et al. | Pulm Ther
Aim: To describe the mechanisms of action of prone position, systematically appraise the current experience of prone position in COVID-19 patients, and highlight unique considerations for prone position practices during this pandemic.
CANDIDATE THERAPEUTICS
|
|
|
10/22/20
|
Hernandez AV, Roman YM, Pasupuleti V, et al. | Ann Intern Med
Aim: To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19). UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/22/20
|
Ayele Mega T, Feyissa TM, Dessalegn Bosho D, et al. | Can Respir J
Aim: To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/21/20
|
Agstam S, Yadav A, Kumar MP, et al. | Indian Pacing Electrophysiol J
Aim: To study the risk of QTc prolongation and Torsades de pointes (TdP) by a well-defined criterion for HCQ, CQ alone, and in combination with Azithromycin in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/21/20
|
Bhattacharyya A, Kumar S, Sarma P, et al. | Indian J Pharmacol
Aim: To evaluate the safety as well as efficacy of L/R combination therapy in the management of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/20/20
|
Kotecha P, Light A, Checcucci E, et al. | Panminerva Med
Aim: To evaluate the data currently available regarding the repurposing of different drugs for Covid-19 treatment. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/20/20
|
Sun C, Sun Y, Li X | Am J Emerg Med
Aim: To evaluate the clinical efficacy and safety of CM in the treatment of COVID-19 pneumonia.
CANDIDATE THERAPEUTICS
|
|
|
10/19/20
|
Fram G, Wang D, Malette K, et al. | Curr Cardiol Rev
Aim: To evaluate the incidence of cardiotoxicity associated with hydroxychloroquine prior to onset of the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
10/19/20
|
Cantini F, Goletti D, Petrone L, et al. | Drugs
Aim: To assess the clinical impact of different therapies for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/13/20
|
Kashour ZT, Riaz M, Garbati M, et al. | J Antimicrob Chemother
Aim: To systematically evaluate the effect of CQ and HCQ with or without azithromycin (AZ) on outcomes of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/13/20
|
Prodromos C, Rumschlag T | New Microbes New Infect
Aim: To review the efficacy of HCQ against COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/12/20
|
Abdelmoneim AH, Mustafa MI, adlan RHA, et al. | Sudan J Med Sci
Aim: To report and summarize the published evidence on the role of convalescent plasma therapy in the current COVID-19 pandemic.
CANDIDATE THERAPEUTICS
|
|
|
10/10/20
|
Yokoyama Y, Aikawa T, Takagi H, et al. | J Med Virol
Aim: To investigate the effect of ACEI and ARB on mortality and susceptibility to COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
10/9/20
|
Li Y, Li J, Zhang Y, et al. | Chin J Integr Med
Aim: To systematically review the clinical practice guidelines for the treatment of coronavirus disease 2019 (COVID-19) patients with Chinese herbal medicine (CHM), summarize their recommendations and evaluate their qualities.
CANDIDATE THERAPEUTICS
|
|
|
10/9/20
|
Hariyanto TI, Kwenandar F, Japar KV, et al. | Anti-Infective Agents
Aim: To synthesize the latest evidence regarding the effectiveness and safety of remdesivir as a potential treatment candidate against COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/6/20
|
Cheng W, Li Y, Cui L, et al. | Front Pharmacol
Aim: To evaluate the efficacy and safety of corticosteroid therapy in patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/5/20
|
Tlayjeh H, Mhish O, Enani M, et al. | J Infect Public Health
Aim: To systematically review the literature about the association between systemic corticosteroid therapy (CST) and outcomes of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
10/2/20
|
Flumignan RLG, de Sa Tinoco JD, Pascoal PIF, et al. | Cochrane Database Syst Rev
Aim: To assess the effects of prophylactic anticoagulants versus active comparator, placebo or no intervention, on mortality and the need for respiratory support in people hospitalised with COVID?19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/28/20
|
Shrestha DB, Pudhathoki P, Khadka S, et al. | Virol J
Aim: To review the efficacy and safety of favipiravir triphosphate as a treatment for COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/24/20
|
Wang M, Wu T, Zuo Z, et al. | BMJ Support Palliat Care
Aim: To summarize the efficacy and safety of antiviral agents currently in use for COVID-19 treatment. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/21/20
|
Yang T, Chou C, Yang Y, et al. | J Chin Med Assoc
Aim: To address not only the benefits and safety issues of HCQ in COVID-19 treatment and to evaluate the effects in combination with the use of macrolide, especially AZI in therapy.
CANDIDATE THERAPEUTICS
|
|
|
9/21/20
|
Khalaj K, Figueira RL, Antounians L, et al. | J Extracell Vesicles
Aim: To analyse whether EV-based therapies could be effective in treating severe pulmonary conditions that affect COVID-19 patients and to understand their relevance for an eventual therapeutic application to human patients.
CANDIDATE THERAPEUTICS
|
|
|
9/18/20
|
WHO REACT Working Group | JAMA
Aim: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
|
|
|
9/18/20
|
Paknahad Z, Moravejolahkami AR | Endocr Metab Immune Disord Drug Targets
Aim: To review the evidence on the effects of probiotics on incidence, severity, duration, and other clinical manifestations of viral infections especially SARS-CoV-2-induced.
CANDIDATE THERAPEUTICS
|
|
|
9/18/20
|
Campbell CM, Guha A, Haque T, et al. | J Clin Med
Aim: To characterize the current state of immunotherapy trials in COVID-19, and focuses on associated cardiotoxicities, given the importance of pharmacovigilance.
CANDIDATE THERAPEUTICS
|
|
|
9/17/20
|
Dambha-Miller H, Albasri A, Hodgson S, et al. | BMJ Open
Aim: To review evidence on routinely prescribed drugs in the UK that could upregulate or downregulate ACE2 and potentially affect COVID-19 disease. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/15/20
|
Yamamoto V, Bolanos JF, Fiallos J, et al. | J Alzheimers Dis
Aim: To provide a comprehensive review of SARS-CoV-2-induced disease, its mechanism of infection, diagnostics, therapeutics, and treatment strategies, while also focusing on less attended aspects by previous studies, including nutritional support, psychological, and rehabilitation of the pandemic and its management.
CANDIDATE THERAPEUTICS
|
|
|
9/14/20
|
Aziz M, Haghbin H, Sitta EA, et al. | J Med Virol
Aim: To compare the efficacy of addition of TOC to standard of care (SOC) versus SOC in patients with COVID?19.
CANDIDATE THERAPEUTICS
|
|
|
9/14/20
|
Hasan SS, Kow CS, Hadi MA, et al. | Am J Cardiovasc Drugs
Aim: To critically examine the association of RAS inhibitors use with mortality and disease severity in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/14/20
|
Cozzupoli GM, Savastano MC, Galsini B, et al. | J Ophthalmol
Aim: To review and analyze previous studies conducted on ritonavir administration and retinal impairment in a narrative synthesis.
CANDIDATE THERAPEUTICS
|
|
|
9/14/20
|
Zeng M, Li L, Wu Z | PLoS ONE
Aim: To review the evidence on the clinical efficacy and safety of the traditional Chinese medicine Lianhua Qingwen in the treatment of new coronavirus pneumonia (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
9/12/20
|
Hussain N, Yoganathan A, Hewage S, et al. | Expert Rev Anti Infect Ther
Aim: To identify studies pertaining to antivirals, both as sole and combined therapies, in COVID-19 patients and review the clinical outcomes of these treatment methods.
CANDIDATE THERAPEUTICS
|
|
|
9/11/20
|
Usman AS, Siddiqi TJ, Khan MS, et al. | Am J Cardiol
Aim: To conduct a meta-analysis of all available data on the relationship between renin-angiotensin aldosterone system of inhibitors and COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/11/20
|
Sun M, Xu Y, He H, et al. | Int J Infect Dis
Aim: To explore the effectiveness of treatment and predict the potential effects of CP with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/11/20
|
Bakhtawar N, Usman M, Khan MMU | Cureus
Aim: To evaluate the efficacy of convalescent plasma (CP) therapy and its effects on COVID-19 patient outcomes.
CANDIDATE THERAPEUTICS
|
|
|
9/11/20
|
Pathak SK, Salunke AA, Thivari P, et al. | Diabets Metab Syndr
Aim: To evaluate the efficacy of hydroxychloroquine and its related formulations in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/10/20
|
Chastain DB, Stitt TM, Ly PR, et al. | Open Forum Infect Dis
Aim: To assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.
CANDIDATE THERAPEUTICS
|
|
|
9/9/20
|
Razmi M, Hashemi F, Gheytanchi E, et al. | Int Immunopharmacol
Aim: To assess the available data regarding the efficacy of the immunomodulatory drugs used to manage COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/9/20
|
Kow CS, Hasan SS | J Med Virol
Aim: To explore whether the use of metformin was associated with decreased mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
9/9/20
|
Seyedpour S, Khodaei B, Loghman AH, et al. | J Cell Physiol
Aim: To provide a systematic evaluation of the most recent in vitro and in vivo investigations targeting SARS?CoV?2 cell entry.
CANDIDATE THERAPEUTICS
|
|
|
9/8/20
|
Elavarasi A, Prasad M, Seth T, et al. | J Gen Intern Med
Aim: To synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
9/8/20
|
Zang Y, Han X, He M, et al. | Naunyn Schmiedebergs Arch Pharmacol
Aim: To systematically assess the benefits and harms of HCQ for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/8/20
|
Vargas M, Servillo G, Einav S | Eur Rev Med Pharmacol Sci
Aim: To review the evidence on the use of lopinavir/ritonavir for the treatment of SARS, MERS, and SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
9/4/20
|
Sarkar S, Khanna P, Soni KD | J Med Virol
Aim: To evaluate the impact of glucocorticoid therapy in COVID-19 patients based on the publications reported to date.
CANDIDATE THERAPEUTICS
|
|
|
9/3/20
|
de Andrade KRC, da Silva Carvalho VK, Farinasso CM, et al. | Cien Saude Colet
Aim: To evaluate the effects of drug therapies for coronavirus infections.
CANDIDATE THERAPEUTICS
|
|
|
9/3/20
|
Bendezu-Quispe G, Rodirquez-Zuniga MJM, Roman YM, et al. | Rev Peru Med Exp Salud Publica
Aim: To review the evidence on chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, oseltamivir, interferon, atazanavir and anti SARS-CoV-2 serum as therapeutic agents for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
9/2/20
|
Cumpstey AF, Oldman AH, Smith AF, et al. | Cochrane Database of Systematic Reviews
Aim: To address how oxygen therapy should be targeted in adults with ARDS (particularly ARDS secondary to COVID?19 or other respiratory viruses) and requiring mechanical ventilation in an intensive care unit, and the impact oxygen therapy has on mortality, days ventilated, days of catecholamine use, requirement for renal replacement therapy, and quality of life.
CANDIDATE THERAPEUTICS
|
|
|
9/2/20
|
Chan CK, Huang YS, Liao HW, et al | Hypertension
Aim: To review the evidence on the impact of the use of ACEi or ARBs on SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
|
|
|
9/1/20
|
Liu M, Ya G, Yuan Y, et al. | Integr Med Res
Aim: To evaluate the efficacy and safety of LH for treating patients with COVID-19 by a systematic review and meta-analysis.
CANDIDATE THERAPEUTICS
|
|
|
9/1/20
|
Baroutjian A, Sanchez C, Boneva D, et al. | Am J Emerg Med
Aim: To evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence.
CANDIDATE THERAPEUTICS
|
|
|
8/31/20
|
Fiolet T, Guihur A, Rebeaud M, et al. | Clin Microbiol Infect
Aim: To assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared to the standard of care. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/31/20
|
Das RR, Jaiswal N, Dev N, et al. | Front Med
Aim: To review the evidence on the efficacy and safety of using anti-malarial drugs to treat COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/31/20
|
Ullah W, Abdullah HM, Roomi S, et al. | J Clin Med Res
Aim: To review the evidence on the use of hydroxycholorquine to treat COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/31/20
|
Nasir M, Perveen RA, Saha SK, et al. | Mymensingh Med J
Aim: To evaluate the role of favipiravir along with its safety and efficacy for the patients who are suffering from severe acute respiratory distress syndrome due to CoronaVirus-2 (SARS-CoV-2) as re-purposeful use.
CANDIDATE THERAPEUTICS
|
|
|
8/27/20
|
Prodromos CC | New Microbes New Infect
Aim: To review the evidence on cardiac arrhythmic mortality caused by the use of hydroxychloroquine and azithromycin.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Pang W, Liu Z, Li Y, et al. | Integr Med Res
Aim: To evaluate the efficacy and safety of CMD for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Arentz S, Yang G, Goldenberg J, et al. | Adv Integr Med
Aim: To assess the effects of zinc on the incidence, duration and severity of acute upper or lower respiratory tract infections caused by SARS-CoV-2 infection in people of any age and of any zinc status when used as a preventive supplement or as a therapy.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Schloss J, Lauche R, Harnett J, et al. | Adv Integr Med
Aim: To review the evidence on the effect of Vitamin C on acute respiratory tract infections in adults when administered at the onset of symptoms.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Frediansyah A, Nainu F, Dhama K, et al. | Clin Epidemiol Glob Health
Aim: To summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Hariyanto TI, Kurniawan A | Diabetes Metab Syndr
Aim: To analyze the association between statin use and in-hospital outcomes of COVID-19 infection.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Siordia JA, Bernaba M, Yoshino K, et al. | SN Compr Clin Med
Aim: To compile the current data regarding human controlled COVID-19 treatment trials.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Leeson CE, Ismail A, Hashad MM, et al. | SN Compr Clin Med
Aim: To review and summarize what is known about COVID-19 and the current implications of intravesical BCG with regard to the disease.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Aucoin M, Cooley K, Saunders PR, et al. | Adv Integr Med
Aim: To review the role of quercetin in the treatment and recovery of COVID-19 and other respiratory tract infections.
CANDIDATE THERAPEUTICS
|
|
|
8/26/20
|
Aucoin M, Cooley K, Saunders PR, et al. | Adv Integr Med
Aim: To review the role of Echinacea in the prevention and treatment of COVID-19 and other respiratory tract infections.
CANDIDATE THERAPEUTICS
|
|
|
8/25/20
|
Baral R, White M, Vassiliou VS | Curr Atheroscler Rep
Aim: To review the evidence on the impact RAAS inhibitor use has in antihypertensive COVID-19 hospitalised patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/23/20
|
Jovic TH, Ali SR, Ibrahim N, et al. | Nutrients
Aim: To investigate whether vitamin supplementation is beneficial in COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/21/20
|
Karlsen APH, Wiberg S, Laigaard J, et al. | PLoS One
Aim: To provide a global snapshot overview of interventions and main methodological aspects of planned and initiated randomised clinical trials on COVID-19 prevention and treatment.
CANDIDATE THERAPEUTICS
|
|
|
8/21/20
|
Talaie H, Hosseini SM, Nazari M, et al. | Daru
Aim: To synthesize the results of well-done observational studies and clinical trials to estimate the value of some clinical managements to confront COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/21/20
|
Abdel-Maboud M, Menshawy A, Elgebaly A, et al. | J Thromb Thrombolysis
Aim: To investigate whether prophylactic heparin use is associated with reduction in thromboembolic events.
CANDIDATE THERAPEUTICS
|
|
|
8/20/20
|
Misra S, Nath M, Hadda V, et al. | Eur J Clin Invest
Aim: To assess the efficacy of various treatment modalities in nCOV-2019 patients.
CANDIDATE THERAPEUTICS
|
|
|
8/19/20
|
Elsawah H, Elsokary MA, Elrazzaz M, et al. | J Med Virol
Aim: To assess the evidence strength of hydroxychloroquine efficacy in treating COVID-19 arising from clinical trials and to update the practice with the most reliable clinical evidence.
CANDIDATE THERAPEUTICS
|
|
|
8/19/20
|
Luo X, Ni X, Lin J, et al. | Phytomedicine
Aim: To investigate the efficacy and safety of CHM or CHM combination therapy for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/15/20
|
Fan AF, Gu S, Alemi AF, et al. | J Integr Med
Aim: To summarize contemporary studies that report the use of Chinese herbal medicine (CHM) to treat COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/15/20
|
Rakedzon S, Khoury Y, Rozenberg G, et al. | Rambam Maimonides Med J
Aim: To review the existing clinical evidence of HCQ use for the prevention and treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/12/20
|
Kow CS, Hasan SS | Am J Cardiol
Aim: To summarise the existing evidence on the effect of statins on the clinical outcomes of COVID-19 from adjusted analyses.
CANDIDATE THERAPEUTICS
|
|
|
8/11/20
|
Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis
Sarkar S, Soni KD, Khanna P | J Med Virol
Aim: To evaluate the impact of CPT in COVID-19 patients based on the publications reported to date.
CANDIDATE THERAPEUTICS
|
|
|
8/9/20
|
Xu X, Shi Y, Wang R, et al. | Integr Med Res
Aim: To comprehensively summarize and analyze the current guidelines on home-based traditional Chinese medicine (TCM) nursing interventions for discharged patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/9/20
|
Barochiner J, Martinez R | J Clin Pharm Ther
Aim: To compare the occurrence of severe and fatal COVID-19 in infected patients who were under treatment with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs no treatment or other antihypertensives. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/9/20
|
Baladia E, Pizarro AB, Ortiz-Munoz L, et al. | Medwave
Aim: To provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/7/20
|
Liu X, Long C, Ziong Q, et al. | Clin Cardiol
Aim: To review the current evidence and assess the clinical prognosis of COVID?19 patients with or without hypertension treated with ACEs/ARBs.
CANDIDATE THERAPEUTICS
|
|
|
8/7/20
|
Chi G, Lee JJ, Jamil A, et al. | J Clin Med
Aim: To offer benchmark data on the incidence of VTE and to examine the difference in D-dimer levels among anticoagulated COVID-19 patients with and without VTE incident. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
8/3/20
|
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis
Putman M, Chock YPE, Tam H, et al. | Arthritis Rheumatol
Aim: To identify and summarize research that describes the use of antirheumatic disease therapies for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
8/2/20
|
Volpe M, Battistoni A | Int J Cardiol
Aim: To review the evidence on the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, with regard to COVID-19 disease and mortality.
CANDIDATE THERAPEUTICS
|
|
|
8/1/20
|
Hasan SS, Capstick T, Ahmed R, et al. | Expert Rev Respair Med
Aim: To review ARDS-associated mortality and the potential role of systemic corticosteroids in COVID-19 patients.
CANDIDATE THERAPEUTICS
|
|
|
7/30/20
|
Musa A, Pendi K, Hashemi A, et al. | West J Emerg Med
Aim: To review the evidence on the use of remdesivir for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/28/20
|
Jin X, Chua HZ, Wang K, et al. | Integr Med Res
Aim: To summarize all the clinical studies to generate reliable evidence for decision-making on the medicinal value of Squama Manitis.
CANDIDATE THERAPEUTICS
|
|
|
7/28/20
|
Cortegiani A, Ippolito M, Greco M, et al. | Pulmonology
Aim: To describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy. and safety.
CANDIDATE THERAPEUTICS
|
|
|
7/28/20
|
Haiduc AA, Alom S, Melamed N, Harky A | J Card Surg
Aim: To examine the literature evidence behind using extracorporeal membrane oxygenation in COVID?19 patients in a systematic review manner.
CANDIDATE THERAPEUTICS
|
|
|
7/28/20
|
Lan S, Lai C, Huang H, et al. | Int J Antimicrob Agents
Aim: To assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
7/25/20
|
Solis-Garcia Del Pozo J, Galindo MF, Nava E, et al. | Eur Rev Med Pharmacol Sci
Aim: To review the evidence on the role of IL-6 in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/24/20
|
Venkatesulu BP, Chandrasekar VT, Giridhar P, et al. | J Med Virol
Aim: To do a systematic review and critical appraisal of the ongoing clinical trials that are assessing various therapeutic interventions against SARS-CoV-2 with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/21/20
|
Vidali S, Morosetti D, Cossu E, et al. | ERJ Open Res
Aim: To highlight the correlation between elevated D-dimer (an indirect thrombosis marker) and the increased rate of poor prognosis-associated conditions, and to introduce D-dimer-labelled anticoagulant administration as a potentially useful tool to prevent complications and positively influence coronavirus disease 2019 (COVID-19) course.
CANDIDATE THERAPEUTICS
|
|
|
7/20/20
|
Cortegiani A, Ingoglia G, Ippolito M, et al. | J Crit Care
Aim: To evaluate the efficacy and safety of chloroquine and chloroquine-related formulations in patients with SARS-CoV-2 pneumonia and articles describing related in-vitro studies. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/17/20
|
Greco A, Buccheri S, D'Arrigo P, et al. | Eur Heart J Cardiovasc Pharmacother
Aim: To review the evidence on the impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the clinical outcomes of COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/15/20
|
Chandrasekar VT, Venkatesalu B, Patel HK, et al. | J Med Virol
Aim: To assess if any intervention provides mortality benefit, other clinically relevant outcomes and also ascertain the safety profile. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/10/20
|
Piechotta V, Iannizzi C, Chai KL, et al. | Cochrane Database Syst Rev
Aim: To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID?19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
7/10/20
|
Yu C, Kang L, Chen J, et al. | Int Immunopharmacol
Aim: To recapitulate relevant studies to evaluate the safety, efficacy, tolerability and treatment-related outcomes of type I IFNs for coronavirus infection in clinical practice, with expectation to provide more robust evidence whether IFNs should be served as first-line agents for coronavirus infection, including the SARS-CoV-2.
CANDIDATE THERAPEUTICS
|
|
|
7/8/20
|
Sun M, Xu Y, He H, et al. | Int J Infect Dis
Aim: To explore the effectiveness of treatment and predict the potential effect of convalescent plasma for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/8/20
|
Zhu R, Gao Y, Robert S, et al. | J Transl Med
Aim: To summarize the characteristics of clinical trials for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/6/20
|
Xiong X, Wang P, Su K, et al. | Pharmacol Res
Aim: To evaluate the current clinical evidence on Chinese herbal medicine for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/3/20
|
Huang D, Yu H, Wang T, et al. | J Med Virol
Aim: To evaluate the efficacy and safety of umifenovir in COVID?19.
CANDIDATE THERAPEUTICS
|
|
|
7/1/20
|
Alizadeh F, Khodavandi A | IEEE Trans Nanobioscience
Aim: To summarize the available evidence on the efficacy of nanoscale materials against coronaviruses in vitro and in animal models.
CANDIDATE THERAPEUTICS
|
|
|
7/1/20
|
Munir MA, Kuganda H, Basry A | Sys Rev Pharm
Aim: To review the evidence on the best and safe antivirus medication to cure COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
7/1/20
|
Flacco ME, Martellucci CA, Bravi F et al. | Heart
Aim: To summarise the existing evidence on the association between these medications and severe/lethal COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/23/20
|
Lu S, Zhou Q, Huang L, et al. | Ann Transl Med
Aim: To review the evidence on the use of glucocorticoids in treating COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/23/20
|
Zhang J, Yang Y, Yang N, et al. | Ann Transl Med
Aim: To explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/23/20
|
Wang J, Tang Y, Ma Y, et al. | Ann Transl Med
Aim: To evaluate the efficacy and safety of antibiotic agents in children with COVID-19, as well as to introduce the present situation of antibiotics use and bacterial coinfections in COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/23/20
|
Shi Q, Zhou Q, Wang X, et al. | Ann Transl Med
Aim: To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
6/20/20
|
Maldonado E, Tao D, Mackey K | J Gen Intern Med
Aim: To synthesize evidence on thromboembolism incidence and outcomes with antithrombotic therapies in COVID-19. UPDATED VA ESP
CANDIDATE THERAPEUTICS
|
|
|
6/17/20
|
Di Lorenzo G, Di Trolio R, Kozlakidis Z, et al. | Crit Rev Oncol Hematol
Aim: To review the evidence on the clinical outcomes of COVID-19-positive patients and the possible interactions between drugs used in experimental therapy of COVID-19 and commonly used antineoplastic drugs.
CANDIDATE THERAPEUTICS
|
|
|
6/14/20
|
Heidary F, Gharebaghi R | J Antibiot (Tokyo)
Aim: To summarize the antiviral effects of ivermectin by reviewing available in vivo and in vitro studies over the past 50 years.
CANDIDATE THERAPEUTICS
|
|
|
6/13/20
|
Zhu T, Xu A, Bai X, et al. | Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
Aim: To systematically review evidence for the effect of convalescent plasma and immunoglobulin on treatment of severe acute respiratory syndrome (SARS), and further provide advice on the treatment of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
6/9/20
|
Patel TK, Barvaliya M, Kevadiya BD, et al. | J Neuroimmune Pharmacol
Aim: To find out early trends of mortality in COVID-19 patients treated with hydroxychloroquine based on published literature.
CANDIDATE THERAPEUTICS
|
|
|
6/9/20
|
Nasir M, Talha KA, Islam T, et al. | Mymensingh Med J
Aim: To evaluate the available evidence on efficacy, safety to identify any promising role for compassionate use of remdesivir in patient suffered for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as re-purposeful use.
CANDIDATE THERAPEUTICS
|
|
|
6/8/20
|
Lima WG, Brito J, Overhage J, et al. | Arch Virol
Aim: To describe the drug repositioning strategy against SARS-CoV-2 and to discuss the clinical impact of this approach in the current pandemic context.
CANDIDATE THERAPEUTICS
|
|
|
6/5/20
|
Bhagavathula AS, Aldhaleei WA, Rovetta A, et al. | Cureus
Aim: To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020.
CANDIDATE THERAPEUTICS
|
|
|
6/4/20
|
Ye Z, Wang Y, Colunga-Lozano LE, et al. | CMAJ
Aim: To examine the impact of corticosteroids in COVID-19 and related severe acute respiratory illnesses to support a guideline for managing COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
6/3/20
|
Liu W, Zhou P, Chen K, et al. | CMAJ
Aim: To support the development of a COVID-19 management guideline by reviewing evidence that addressed the benefits and harms of 7 antiviral treatments for COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/28/20
|
Das S, Bhowmick S, Tiwari S, et al. | Clin Drug Investig
Aim: To systematically review the therapeutic role of HCQ in COVID-19 from the available literature.
CANDIDATE THERAPEUTICS
|
|
|
5/27/20
|
Fajgenbaum DC, Khor JS, Gorzewski A, et al. | Infect Dis Ther
Aim: To systematically evaluate the treatments adminstered to COVID-19 patients. UPDATED
CANDIDATE THERAPEUTICS
|
|
|
5/26/20
|
Rodrigo C, Fernando SD, Rajapakse S | Clin Microbiol Infect
Aim: To summarize evidence from human clinical studies for using HCQ or CQ as antiviral agents for any viral infection.
CANDIDATE THERAPEUTICS
|
|
|
5/23/20
|
Ang L, Song E, Lee HW, et al. | J Clin Med
Aim: To evaluate the effectiveness and adverse events of herbal medicines for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/22/20
|
Devasenapathy N, Ye Z, Loeb M, et al. | CMAJ
Aim: To review the safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) patients for guideline development
CANDIDATE THERAPEUTICS
|
|
|
5/21/20
|
Antwi-Amoabeng D, Kanji Z, Ford B, et al. | J Med Virol
Aim: To summarize the baseline characteristics of COVID-19 patients who received tocilizumab in order to identify nuanced predictors of response to therapy and other clinical outcomes.
CANDIDATE THERAPEUTICS
|
|
|
5/20/20
|
Nemati H, Ramezani M, Najafi F, et al. | Open Access Maced J Med Sci
Aim: To check the association between ACE2 and COVID-19 (coronavirus disease 2019) in a systematic review.
CANDIDATE THERAPEUTICS
|
|
|
5/19/20
|
Sachdeva M, Mufti A, Maliyar K, et al. | J Am Acad Dermatol
Aim: To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment.
CANDIDATE THERAPEUTICS
|
|
|
5/15/20
|
Zhang X, Yu J, Pan L, et al. | Pharmacol Res
Aim: To (1) determine whether use of ACRI/ARB is associated with an increase in likelihood of viral infectivity; (2) to investigate whether there are differences in severity and mortality between ACRI/ARB users and non- ACRI/ARB users; (3) and, in particular, to evaluate whether ACRI/ARB exposure was associated with a lower risk of mortality when compared to non-ACRI/ARB antihypertensive drug exposure.
CANDIDATE THERAPEUTICS
|
|
|
5/14/20
|
Gbinigie K, Frie K | BJGP Open
Aim: To review the evidence for the effectiveness and safety of azithromycin in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/12/20
|
Singh AK, Singh A, Shaikh A, et al. | Diabets Metab Syndr
Aim: To review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.
CANDIDATE THERAPEUTICS
|
|
|
5/12/20
|
Rajendran K, Narayanasamy K, Rangarajan J, et al. | J Med Virol
Aim: To evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date.
CANDIDATE THERAPEUTICS
|
|
|
5/12/20
|
Veronese N, Demurtas J, Yang L, et al. | Front Med
Aim: To investigate the effectiveness of glucocorticoid therapy in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/11/20
|
Patil VM, Singhal S, Masand N | Life Sci
Aim: To review the evidence on the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine.
CANDIDATE THERAPEUTICS
|
|
|
5/11/20
|
Ricco M, Gualerzi G, Ranzieri S et al. | Acta Biomed
Aim: To review the evidence on the role of the BCG vaccine as a preventive and/or therapeutic option against COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
5/10/20
|
Liu M, Gao Y, Yuan Y, et al. | Pharmacol Res
Aim: To assess the efficacy and safety of Integrated Traditional Chinese and Western Medicine to corona virus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
|
|
|
5/10/20
|
Jankelson L, Karam G, Becker ML, et al. | Heart Rhythm
Aim: To conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine.
CANDIDATE THERAPEUTICS
|
|
|
5/8/20
|
Li Z, Wang X, Cao D, et al. | Drug Discov Ther
Aim: To critically assess the potential anti-coronavirus effect of remdesivir on COVID-19 and other coronaviruses based on the most up-to-date evidence.
CANDIDATE THERAPEUTICS
|
|
|
5/5/20
|
Li H, Chen C, Hu F, et al. | Leukemia
Aim: To determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections.
CANDIDATE THERAPEUTICS
|
|
|
5/2/20
|
Chowdhury M, Rathod J, Gernsheimer J | Acad Emerg Med
Aim: To review literature currently available regarding the clinical use of CQ and HCQ as treatment in COVID-19 patients in an effort to catalog their recommendations and assess drug efficacy.
CANDIDATE THERAPEUTICS
|
|
|
4/30/20
|
Zhong H, Wang Y, Zhang Z, et al. | Pharmacol Res
Aim: To evaluate the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.
CANDIDATE THERAPEUTICS
|
|
|
4/27/20
|
Halpin D, Singh D, Hadfield RM | Eur Respir J
Aim: To evaluate whether pre-morbid use or continued administration of inhaled steroids is a risk factor for adverse outcomes in acute respiratory infections due to COVID-19, SARS or MERS. WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
|
|
|
4/21/20
|
Yousefifard M, Zali A, Mohamed A, et al. | Arch Acad Emerg Med
Aim: To evaluate the efficacy of antiviral therapies in treatment of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/21/20
|
Alzghari SK, Acuna VS | J Clin Virol
Aim: To evaluate outcomes associated with TCZ treatment in patients with COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/17/20
|
Tobaigy M, Qashgary M, Al-Dahery S, et al. | Infect Prev Pract
Aim: To report any evidence of therapeutics used for the management of COVID-19 patients in clinical practice since the emergence of the virus.
CANDIDATE THERAPEUTICS
|
|
|
4/17/20
|
Sarma P, Kaur H, Kumar H, et al. | J Med Virol
Aim: To examine the evidence for the safety and efficacy of hydroxycholorquine in COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/14/20
|
Shah S, Das S, Jain A, et al. | Int J Rheum Dis
Aim: To systematically review the role of CQ and HCQ in preventing the spread of COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/14/20
|
Yang Z, Liu J, Zhou Y, et al. | J Infect
Aim: To further evaluate the influence of corticosteroids on patients with coronavirus infection.
CANDIDATE THERAPEUTICS
|
|
|
4/10/20
|
Aminjafari A, Ghasemi S | Int Immunopharmacol
Aim: To evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV.
CANDIDATE THERAPEUTICS
|
|
|
4/9/20
|
Gbinigie K, Kerstin F | BJGP Open
Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.
CANDIDATE THERAPEUTICS
|
|
|
4/1/20
|
Roman BR, Moscoso S, Chung SA, et al. | Revista Cubana de Farmacia
Aim: To review the evidence about the effectiveness and adverse reactions of the drugs currently used against COVID-19 in Peru and Bolivia.
CANDIDATE THERAPEUTICS
|
|
|
3/29/20
|
Lin A, Hye W, Jun Y, et al. | Integr Med Res
Aim: To summarize and analyze the herbal formulae provided by the guidelines for their pattern identifications (PIs) and compositions of herbs to treat patients with COVID-19
CANDIDATE THERAPEUTICS
|
|
|
2/25/20
|
Rios P, Radhakrishnan A, Antony J, et al. | Public Health Agency of Canada
Aim: To identify safe and effective medical countermeasures (e.g., antivirals/antibodies) to address the current outbreak of a novel coronavirus (COVID-19)
CANDIDATE THERAPEUTICS
|
|
|
2/14/20
|
Zhang L, Liu Y | J Med Virol
Aim: To summarize therapeutic options available for the treatment of COVID-19
CANDIDATE THERAPEUTICS
|
|
|
2/1/20
|
Prajapat M, Sarma P, Shekhar N, et al. | Indian J Pharmacol
Aim: To describe protein structures that are potential targets for the development of CoV therapies
CANDIDATE THERAPEUTICS
|
Collections
Candidate Therapeutics
Clinical Characteristics
Diagnostics
Infection Control
Long COVID
Mental Health
Powered by the VA Evidence Synthesis Program
|| Website by the Scientific Support Center SSC
© ESP 2020